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Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer,
the fourth leading cause of cancer-related deaths in the USA with over 40,000 deaths per
year. Unlike other major cancer types, the progress in dealing with PDAC is plodding,
attributed mainly to the asymptomatic nature of the disease, the late diagnosis and the
ineffectiveness of current therapies. A better understanding of the biology of the disease
could permit the discovery of novel diagnostic and therapeutic tools. With that in mind, we
present this dissertation that investigates the tumor-stromal interaction underlined by
genetic alterations and inflammation. PDAC develop as a consequence of the
accumulation of genetic mutations like Kras. Oncogenic Kras is known to propagate
inflammatory signals such as CXCR2. PDAC is known for the prominent desmoplasia that
enables therapy resistance and tumor dissemination, which is mainly mediated through
cancer-associated fibroblasts (CAFs). Little is known about the connection between
oncogenic Kras, CXCR2 signaling and CAFs. In this study, we show that CAFs can
produce CXCR2 ligands and can respond to CXCR2 signaling. We indicated that through
paracrine factors such as CXCL8 and FGF-2, CAFs support the survival of the aggressive
PDAC cells and enable means for progression. We demonstrate that oncogenic Kras is
associated with a subset of CAFs with a prominent secretory function mediated through
CXCR2 signaling. Lastly, we exhibit a differential role of CXCR2 in PDAC that was
dependent on genetic mutations, which may indicate a temporal context of CXCR2 roles
in PDAC. Together, CAFs, as well as CXCR2, could still be worthy targets in PDAC in the
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right context. Further studies that investigate the progression and timely roles of CAFs
and CXCR2 are warranted.
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CHAPTER I: INTRODUCTION

This chapter in part is derived from:
Awaji M and Singh RK. Cancer-associated fibroblasts functional heterogeneity in
pancreatic
ductal
adenocarcinoma.
Cancers,
11(3):290-304,
2019.
doi:10.3390/cancers11030290
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SIGNIFICANCE OF THE STUDY
Pancreatic cancers (PC), particularly pancreatic ductal adenocarcinoma
(PDAC), have a very poor prognosis that often leads to deaths. The major
challenge in dealing with the disease is that it is presented at a very advanced
stage often when PDAC has already disseminated to other organs. PDAC is also
characterized by high recurrence rates and frequent resistance to conventional
therapies. Finding screening and diagnostic tools that can detect the disease early
when it is still manageable, and developing new therapeutic approaches to deal
with advanced stages PDAC are two cornerstones in successfully dealing with this
malignancy. This starts by understanding the dense and complex tumor
microenvironment of the disease, determining the major players in tumor initiation
and progression, and identifying the crucial checkpoints that determine the tumor’s
fate. Cancer-associated fibroblasts (CAFs) present with abundance in PDAC.
They are known to excessively produce extracellular matrix (ECM) proteins as well
as many paracrine factors. By interacting with malignant cells and other cells in the
tumor microenvironment, CAFs have been implicated in tumor growth,
immunosuppression, therapy resistance, and invasion. This study presents an
effort to understand the role of CAFs in PDAC and their role in promoting tumor
progression, dissemination, or lack thereof via their paracrine interactions. The
finding from this study will help in adding to the current knowledge of the molecular
and histological features of PDAC, thus, aids in classifying and stratifying PDAC,
which will allow more precise new targeted therapy approaches.
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OVERVIEW OF THE PANCREAS: ANATOMY AND PHYSIOLOGY
Anatomy and function:
The pancreas is a retroperitoneal organ of both gastrointestinal and endocrine
systems. It is located in the posterior portion of the upper abdomen behind the
stomach. Pancreas divides into the head (right), body (middle) and tail (left). It
weighs around 100 g and extends to 14-25 cm long. Exocrine pancreas, ~95% of
organ mass, secrets digestive enzymes to the duodenum through the pancreatic
duct at the hepatopancreatic ampulla, through which the common bile duct from
the liver and gallbladder also enters the duodenum. The valve of the sphincter of
Oddi, not only regulates the flow of bile and pancreatic juice into the duodenum
but also prevents the reflux of intestinal contents into the pancreatic duct.
Endocrine pancreas, comprised of islets, secretes insulin, glucagon, somatostatin,
and pancreatic polypeptide into the blood. The junction of the head and body is
referred to as the neck. The neck is thinner than the adjacent portions of the head
and body of the pancreas. Posterior to the neck, run major blood vessels such as
the superior mesenteric artery, superior mesenteric‐portal vein, inferior vena cava,
and aorta, which limits the option for a wide surgical margin during pancreatectomy
(Horan 2009, Longnecker, Gorelick et al. 2018).
Histology:
The two distinct functions of the pancreas are modulated by two discrete
histologic components. The endocrine pancreas that secrets hormones, including
insulin, into the bloodstream is defined as the spherical or ellipsoid structures
3

known as pancreatic islets (islets of Langerhans; dispersed throughout the
exocrine pancreas). The islets contain alpha (α) cells, beta (β) cells, gamma (γ)
cells, delta (δ) cells, epsilon (ε) cells, and pancreatic polypeptide cells. On the other
hand, a network of tubules composed of acinar and duct cells that synthesize,
secrete, and carry digestive enzymes into the intestine makes up the exocrine
pancreas. Acinar cells contain zymogen granules, the storage compartment for
pancreatic digestive enzymes. Acinar cells arrange in clusters, like grapes, at the
ends of a branching duct system. Duct, composed of epithelial cells, make up the
branching ductal system that collects acinar juices to the gastrointestinal system
via the pancreatic duct (Longnecker, Gorelick et al. 2018).
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PANCREATIC CANCER
Epidemiology
When compared to other major human malignancies, PC has a lower
incidence; yet, the disease remains one of the deadliest types (Lowenfels and
Maisonneuve 2006). PC currently ranks as the fourth leading cause of cancerrelated death in the United States of America. PC is expected to take over as the
second leading cause of cancer-related deaths by 2030 (Siegel, Miller et al. 2018).
For the past few years, the American Cancer Society estimated an average of over
50,000 new cases and over 40,000 deaths of PC in both sexes combined. PC is
more common in older people and slightly has a higher incidence in males. The
overall five-year survival rate for PC is 8%. Around 20% of PC patients present
with localized tumors for which surgical resection can improve the survival rate to
32%. Nonetheless, most of the PC cases present clinically at distant metastasis
stage with only a three-percent survival rate (Siegel, Miller et al. 2018). The overall
five-year survival for all cancers combined has improved from 49% in 1977 to 69%
in 2014. In comparison, the survival rate for PC only improved from 3% to 9%
(Siegel, Miller et al. 2018). This poor improvement in patient survival can explain
why the PC is expected to become the second leading cause of cancer-related
deaths after another decade. Furthermore, the disease has a high rate for
recurrence, even for those who undergo surgical resection (Network 2016), as well
as a high chance of developing resistance to conventional therapy (Hidalgo 2010).
The challenges that remain as obstacles in properly improving PC survival rates
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include the late presentation and the lack of early detection tools, and high rates
of distant metastasis, recurrence, and therapy resistance.
Risk factors
There is not yet any described definitive cause for the occurrence of PC.
Many factors have been identified as risk factors for PC, including smoking,
obesity, physical inactivity, genetic predisposition, diabetes, and certain diets
(Lowenfels and Maisonneuve 2006, Raimondi, Maisonneuve et al. 2009).
Based on descriptive epidemiology, factors like ages, gender or
geographical location can impact the rate of PC occurrence. PC is common in older
people. The median age of diagnosis of PC is 72 years. Only about less than 10%
of patients develop PC are under 50 (Raimondi, Maisonneuve et al. 2009). The
American Cancer Society reports the comparatively highest number of deaths
10,594 (males) and 9,076 (females) in the age group of 60-79 years in comparison
to other age groups (Siegel, Miller et al. 2018). Moreover, PC presents with higher
occurrence in males than in females (Lowenfels and Maisonneuve 2006,
Raimondi, Maisonneuve et al. 2009). Race as well can play a role. AfricanAmericans have a higher tendency to get PC than white-Americans. Even so,
countries and locations closer to the equator such as Egypt and Zimbabwe have
lower rates of PC than northern countries such as Finland and Iceland (Raimondi,
Maisonneuve et al. 2009).
Environmental factors such as smoking and specific diets may increase the
risk of PC. Exposure to tobacco smoke is associated with about 25% of PC cases
6

(Lowenfels and Maisonneuve 2006, Raimondi, Maisonneuve et al. 2009).
Cigarettes-smokers have around 75% higher risk of PC than non-smokers, and
this increased risk persists for at least ten years after smoking cessation (Ilic and
Ilic 2016). Furthermore, increased body-mass-index, both general and abdominal
obesity, and increased caloric consumption have been linked to the risk of PC
(Lowenfels and Maisonneuve 2006, Aune, Greenwood et al. 2011).
Certain people have a predisposition for PC. Around 10% of PC cases are
linked to germline mutations. Certain familial syndromes, such as, Peutz-Jeghers
syndrome, familial atypical mole-multiple melanoma, cystic fibrosis and LiFraumeni syndrome are also linked to increased rate of PC (Raimondi,
Maisonneuve et al. 2009). Furthermore, preexisting diseases, such as diabetes
and pancreatitis, are linked with increased risk of PC (Lowenfels and Maisonneuve
2006, Raimondi, Maisonneuve et al. 2009).
Histological classification of pancreatic cancer
As the pancreas is divided histologically and functionally into the endocrine
and exocrine pancreas, PCs are often classified as such. Endocrine PCs are far
less common than exocrine malignancies and often milder. The survival time of
patients with endocrine PC is normally two years longer than those diagnosed with
exocrine PC (Fesinmeyer 2005). Endocrine tumors are relatively rare, arise in the
islet cells and are referred to as islet cell or pancreatic neuroendocrine tumors.
Their nomenclature is based on the hormone they overproduce. They are subclassified into insulinoma, glucagonoma, somatostatinoma or nonfunctional islet
cell tumors. The endocrine pancreatic tumors often overproduce normally
7

occurring substances, such as, insulin and glucagon; exocrine PC tumors are often
harsher. Some exocrine malignancies may block pancreatic duct causing jaundice
and cachexia (Fesinmeyer 2005). Since the vast majority of PCs are exocrine
tumors, we will dedicate the next part to discussing exocrine tumors.
Malignancies of the exocrine pancreas
As described, the exocrine pancreas is mainly made of clusters of acinar
cells that secrete digestive enzymes into the branching duct made of ductal
epithelial cells (Longnecker, Gorelick et al. 2018). The vast majority of exocrine
PCs are ductal adenocarcinomas (Hruban and Fukushima 2007). Less common
types of exocrine tumors include cystic tumors that cause a cyst or fluid-filled sac
in the pancreas and cancer of the acinar cells. According to World Health
Organization and International Agency for Research on Cancer (Bosman, Carneiro
et al. 2010), exocrine pancreas malignancies can be classified as follows: PDAC
(75% cases), serous cystadenoma, mucinous cystadenocarcinoma, intra-ductal
papillary-mucinous carcinoma, and acinar cell carcinoma. PDAC can be further
divided into differentiated and poorly differentiated. Other rare forms of exocrine
PCs include pancreatoblastoma that affects children and solid pseudopapillary
tumors, a rare low-grade neoplasm that mainly affects younger women and has a
very good prognosis (Fesinmeyer 2005, Bosman, Carneiro et al. 2010). Because
PDAC is the most frequent exocrine tumors with the poorest prognosis, we will
mainly focus on discussing PDAC in this dissertation.
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PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Overview
The cellular phenotype of the PDAC malignant cells is similar to ductal
epithelial cells of the exocrine pancreas (Kloppel, Lingenthal et al. 1985, Hruban,
Adsay et al. 2001); however, the exact origin is still debated. PDAC may arise from
a poorly differentiated ductal cell, a dedifferentiated acinar or islet cell, or a
progenitor or stem cell (Li, Lee et al. 2009). PDAC account for 85-90% of all
pancreatic neoplasms and is very virulent in nature (Hruban and Fukushima 2007).
PDAC can block the pancreatic duct, which results in jaundice and cachexia
(Modolell, Guarner et al. 1999, Porta, Fabregat et al. 2005). At the time of
diagnosis, 52% of the patients present with a disease that has already
metastasized to other organs (Siegel, Miller et al. 2018). PDAC tumors are often
firm, but poorly defined in structure with a tendency to invade nearby tissues.
Anatomically, 65% of PDAC tumors arise in the head; whereas, around 25% occur
in the body and tail. It is common for the tumors in the head to invade the common
bile duct or the main pancreatic duct and produce stenosis. In contrast, tumors of
the pancreatic body and tail obstruct the main pancreatic duct only (Hruban and
Fukushima 2007). Histologically, PDAC is featured with the presence of a dense
stromal response known as desmoplasia. Under the microscope, PDAC lesions
imitate the appearance of normal pancreatic ducts embedded inside a thick stroma
(Figure 1.1). The desmoplastic stroma in PDAC is known to be composed of
fibroblasts, stellate cells, endothelial and immune cells (Kloppel, Lingenthal et al.
1985, Hruban, Adsay et al. 2001). The large amount of fibrous stroma explains the
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firm consistency of PDAC tumors. PDAC, similar to many other malignancies, does
not arise in isolation. The disease progresses over a long period with the
contribution of many factors, including, progressive genetic alterations in the
malignant cells, as well as contribution from other host cells in the tumor
microenvironment. In the next few sections, we will discuss how PDAC progresses,
the genetic alterations to allow this progression and the contribution of
inflammation and stroma in this disease.
PDAC precursor lesions
The end stage invasive PDAC results from the development of precancerous precursor lesions in the pancreas (Hruban, Wilentz et al. 2000, Hruban,
Maitra et al. 2007, Hruban, Brune et al. 2008). Example of these precursor lesions
includes intra-ductal papillary mucinous neoplasm (IPMN) and mucinous cystic
neoplasm (MCN). The most described precursor lesion type is termed pancreatic
intra-epithelial neoplasia (PanIN) (Hruban, Maitra et al. 2007). PanINs are
microscopic (around ½ cm) neoplastic proliferation in the pancreatic ducts that
develop into three histologically distinct stages (PAnIN1-3), before becoming a fullblown invasive PDAC. PanIN1 lesions are composed of columnar epithelial cells
with basally oriented nuclei and abundant mucin production and can be either flat
(PanIN1A) or papillary (PanIN1B) (Hruban, Brune et al. 2008). PanIN-2 are mostly
papillary with some nuclear abnormalities including loss of nuclear polarity, nuclear
crowding, and variations in size, hyperchromasia and nuclear pseudostratification
(Hruban, Brune et al. 2008). PanIN-3 lesions show the highest form of dysplasia
and are

architecturally complex with
10

marked

cytological abnormalities,

cirbriforming, budding off of epithelial cells and luminal necrosis (Hruban, Brune et
al. 2008). Progression from PanIN-1 to PanIN-3 stage occur in stepwise and is
accompanied by the onset of various mutations (Hansel, Kern et al. 2003, Hruban,
Maitra et al. 2007, Hruban, Brune et al. 2008).
Genetic alterations in PDAC
Molecular and genetic analysis of PDAC indicated that most of the
mutations found in the invasive stages are also present in precursor lesions
(Feldmann, Beaty et al. 2007). Such a thing suggests that these lesions occur in
conjunction with the accumulation of genetic mutations.
The signature genetic events of PDAC lesions include mutations of Kras,
CDKN2A, TP53, BRCA2, and Smad4/DPC4, among many others (Kern, Schutte
et al. 1995, Hansel, Kern et al. 2003, Löhr, Klöppel et al. 2005, Hruban and Adsay
2009). With the progression of PanINs to higher grades, the number of genetic
alteration increase. Activating mutations in the Kras oncogene are detected very
early in tumor progression (Feldmann, Beaty et al. 2007). Other notable events
include mutations of CDKN2A, TP53, and SMAD4 that happen as a result of the
loss of heterozygosity at chromosome 9q, 17p and 18q respectively (Siegel and
Massagué 2003, Maitra and Hruban 2008). As the focus of this thesis is to
elucidate the role of the CAFs in conjunction with the paracrine signaling in PDAC
development and progression, we will only discuss the details of Kras and SMAD4
mutations.
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Activating Kras mutations (will be referred to henceforth as oncogenic Kras),
are among the earliest genetic events and are found in nearly 95% of PDAC cases
(Feldmann, Beaty et al. 2007). Kras is a member of the RAS family, small GTPases
with 21-30kDa in size. These RAS proteins reverse between a GTP-bound onstate and GDP-bound off-state. Kras is the only RAS protein that has been
reported to mutate in PDAC. A point mutation in this protein results in constitutive
activation of RAS leading to persistent downstream signaling. The predominant
version occurs at position G12; but activating mutations at other positions have
been identified as well (Löhr, Klöppel et al. 2005, Feldmann, Beaty et al. 2007).
Oncogenic Kras allows the malignant cells in PDAC to attain more survival,
proliferation, cytoskeletal remodeling and motility (Bryant, Mancias et al. 2014).
Oncogenic Kras is associated with increase tumor-supporting inflammatory
response such as CXCR2 signaling (Ling, Kang et al. 2012, Baumgart, Chen et al.
2014, Purohit, Varney et al. 2016). During the course of this thesis, we will discuss
how oncogenic Kras and CXCR2 can play a role in CAFs orientation and function
in PDAC.
Smad4, also known as DPC4 (deleted in pancreatic cancer 4), is a member
of Smad proteins that mediate signal transduction for a variety of pathways in
which transforming growth factor beta (TGF-β) pathway is the most relevant
(Blobe, Schiemann et al. 2000, Massagué 2012). TGF-β, a multifunctional
cytokine, often found in in the extracellular matrix and is produced by
macrophages, lymphocytes, fibroblasts, epithelial cells, and platelets. TGF-β is
vital in prenatal and postnatal development, organ maintenance and homeostasis,
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and wound healing (Blobe, Schiemann et al. 2000, Massagué 2012). Intact TGFβ/Smad4 signaling works as a tumor suppressor by blocking cell cycle progression,
inducing apoptosis of epithelial cells, and maintaining genomic integrity and tissue
hemostasis (Liu, Pouponnot et al. 1997, Massagué 2008, Ahmed, Bradshaw et al.
2017). Smad4 inactivation results in ligand accumulation that signal in tumor cells
(in a Smad-independent manner) as well as in stromal cells (Zhang 2009). Loss
of Smad4 activates non-smad TGF-β pathways including Erk MAPK and JNK/p38
MAPK pathways that play an essential role in epithelial-mesenchymal transition
(EMT). Besides, TGF-β mediates EMT, cytoskeletal organization and motility via
Rho-like GTPases, RhoA and Rac (Masamune, Kikuta et al. 2003, Massagué
2008). In fibroblasts, TGF-β is known to induce activation and EMC deposition
Furthermore, sustained TGF-β inhibits the synthesis of Matrix Metalloproteinases
(MMPs), thus, inhibiting degradation of newly synthesized ECM (Shek, Fmj et al.
2002). In PDAC, elevated TGF-β levels are found in both plasma and tumor
tissues. The role of TGF-β in regulating EMT and tumor stiffness could explain how
high TGF-β expression and the loss of Smad4 correlate with metastasis and poor
survival in PDAC (Tascilar, Skinner et al. 2001, Tang, Katuri et al. 2005, Blackford,
Serrano et al. 2009, Singh, Srinivasan et al. 2012, Xia, Wu et al. 2014).
Tumor microenvironment of PDAC
Mutations associated with malignancies often enable tumor cells to have
sustained signals for growth; however, these events are not enough to maintain
the tumor’s overall autonomous survival. Several kinds of normal host cells are
recruited and oriented by malignant cells to support tumor growth and progression
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(Hanahan and Weinberg 2000, Hanahan and Weinberg 2011). One of the
hallmarks of PDAC is the presence of dense desmoplasia in the tumor
microenvironment of this disease. Desmoplasia in PDAC account for 80-90% of
the overall tumor mass and can be defined as the exuberant proliferation of stromal
cells, abundant production of ECM with increased collagen deposition (Chu,
Kimmelman et al. 2007, Kleeff, Beckhove et al. 2007). This desmoplastic reaction
has been implicated in resistance to chemotherapy and radiotherapy and can be
attributed to the hypovascularity often observed in PDAC. The stromal
compartment in PDAC is composed of multiple cell types including fibroblasts,
immune cells, endothelial cells, and ECM proteins. It has been demonstrated that
cancer stroma plays an active and dynamic role in tumor growth, invasion, and
metastasis (McAllister and Weinberg 2010).
Inflammation in PDAC
It has been established that both innate and adaptive immune cells present
at sites of many tumors including PDAC (Chu, Kimmelman et al. 2007, Kleeff,
Beckhove et al. 2007). There is more evidence now that support the notion of the
tumor supporting-inflammation in regard to the presence of immune cells at the
tumor site. Inflammation can contribute to cancer progression by supplying several
molecules to enable sustained tumor growth, prevent tumor eradication, facilitate
angiogenesis, and promote invasion and metastasis (DeNardo and Coussens
2007, Grivennikov, Greten et al. 2010, Qian and Pollard 2010).
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Paracrine factors derived from malignant cells and stromal cells orchestrate
the recruitment and the orientation of the different components of the tumor
microenvironment to facilitate tumor progression (Pietras and Östman 2010,
Matsuo, Takeyama et al. 2012). CXCR2, a chemokine receptor, axis plays a key
role during PDAC initiation and progression. CXCR2 and its ligands are linked to
increased tumor cell proliferation, pro-tumor immunosuppression and resistance
to therapy (Chan, Hsu et al. 2016, Purohit, Varney et al. 2016, Steele, Karim et al.
2016).
In this dissertation, we discuss the contribution of paracrine interaction
between malignant cells and CAFs in tumor progression or lack thereof.
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CXCR2 SIGNALING
Overview
Chemotactic cytokines, i.e., chemokines, are small secreted molecules that
are either homeostatic or inflammatory. They are known to play roles in multiple
cellular processes such as leukocyte migration, embryogenesis, angiogenesis,
and hematopoiesis. Homeostatic chemokines have a constitutive expression in
specific cell types and tissues to maintain tissue homeostasis and development.
In contrast, inflammatory chemokines are inducible and up-regulated by
inflammatory stimuli (Vandercappellen, Van Damme et al. 2008). Structurally,
based on the position of the conserved N-terminal cysteine residues, they are
classified into four families: C, CC, CXC, and CX3C. Chemokine receptors are
members of the seven-transmembrane G-protein coupled receptor family. CXCR2
is the receptor for a group of inflammatory and angiogenic chemokines referred to
as Glutamic acid-Leucine-Arginine (ELR)+ CXC chemokines that include CXCL13, 5-7, and 8 that also interacts with CXCR1(Strieter, Burdick et al. 2006, Lazennec
and Richmond 2010). Several studies have reported that CXCR2 and its ligands
play an important role in regulating tumor growth, angiogenesis, and metastasis in
PDAC and many other tumors (Strieter, Burdick et al. 2006, Singh, Sadanandam
et al. 2007, Wang, Wu et al. 2013, Purohit, Varney et al. 2016). To understand the
role of CXCR2 in PDAC, we will first discuss the role of CXCR2 during
physiological inflammation.
CXCR2 signaling during inflammation
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CXCR2 is known to mediate many processes during inflammation. CXCR2
is mainly expressed on several cell types such as neutrophils (Bajrami, Zhu et al.
2016), monocytes (Moser, Barella et al. 1993, Patel, Charlton et al. 2001, Murdoch
2004), mast cells (Maltby, Khazaie et al. 2009, Wynn and Barron 2010), and
endothelial cells (Li, Cheng et al. 2011). Ligation of CXCR2 to its chemokines
induces calcium release, activates Ras/MAPK and PI3K signaling cascades, and
results in many immune responses including directed neutrophil migration (Wu,
Wang et al. 2011). Neutrophils represent the largest component of the innate
immune system. Neutrophils homeostasis is maintained by balancing their release
from bone marrow and their clearance from circulation. CXCL12, a chemokine that
works through CXCR4, has an antagonistic effect to CXCR2. CXCR4 activity
enhances hematopoietic cells retention in the bone marrow. Loss or decreased
activity of CXCR4 results in mobilization of neutrophil to the blood (Eash,
Greenbaum et al. 2010). CXCR2 signaling mediates neutrophil migration from
blood circulation to the inflamed tissue. During an inflammatory response,
neutrophils are one of the first responders. As the first line of host defense against
infection, neutrophils travel to sites of infection to then control the bacterial burden;
however, prolonged and excessive neutrophil infiltration can cause tissue damage.
Recent reports described that that neutrophil recruitment during inflammation
occurs in two phases. The early phase is mediated by short-lived signals, whereas
the amplification phase is mediated through leukotriene-B4 and CXCR2
chemokines (Grivennikov, Greten et al. 2010, de Oliveira, Rosowski et al. 2016).
Tissue remodeling is a crucial step to maintain the structural and functional
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integrity of the inflamed tissue. Following the inflammation clearance, many
processes occur including re-epithelialization, neovascularization (angiogenesis)
and scarring of the collapsed tissue (Devalaraja, Nanney et al. 2000, Midwood,
Williams et al. 2004). Angiogenesis, the formation of new capillary blood vessels,
is essential to provide a supply of nutrients and oxygen to the newly generated
tissues. CXCR2 signaling has a key role in the process of angiogenesis.
Endothelial cells, which form the inner lining of blood vessels, constitutively
express CXCR2 and respond to chemokine stimulation. CXCL8 was reported to
directly enhances endothelial cell proliferation, survival, and their expression of
metalloproteases; thus, regulating angiogenesis (Strieter, Polverini et al. 1995,
Strieter, Burdick et al. 2006, Matsuo, Raimondo et al. 2009).
CXCR2 expression and signaling in PDAC
More compelling evidence for the adverse role of CXCR2 signaling in PDAC
is now available. Both PDAC and the normal pancreas express CXCR2, but PDAC
is more responsive. Oncogenic Kras in PDAC occurs very early, often as soon as
the inception of the PanINs (Feldmann, Beaty et al. 2007). The upregulation of
CXCR2 signaling in PDAC has been reported to be directly linked to oncogenic
Kras (Purohit, Varney et al. 2016). The genetically engineered mouse model
(GEMM; Pdx1-cre;LSL-Kras(G12D) known as KC mouse model) of PDAC exhibited
a progressive increase in the expression of CXCR2 and its ligands in the malignant
ductal cells (Purohit, Varney et al. 2016). Oncogenic KRAS-CXCR2 axis created
a feed-forward loop that contributed to tumor progression by supporting tumor cell
growth. Furthermore, CXCR2 chemokines have been linked with increasing
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migration potentials of malignant cells as well as facilitating resistance to
chemotherapy by the induction of cancer stem cells (CSCs) (Chan, Hsu et al. 2016,
Purohit, Varney et al. 2016).
CXCR2 signaling can additionally aid in the tumor progression, not only by
promoting autonomous aggression characteristic in malignant cells but also
through other cells in the tumor microenvironment (Strieter, Burdick et al. 2006,
Highfill, Cui et al. 2014). We have discussed the role of CXCR2 signaling during
inflammation depicted as facilitating migration of innate immune cells and inducing
angiogenesis. Such features can be utilized adversely by malignant tumors by
enabling recruitment of immunosuppressive cells such as myeloid-derived
suppressor cells (MDSCs) and facilitating tumor invasion through stimulating
angiogenesis (Highfill, Cui et al. 2014, Ramachandran, Condamine et al. 2016).
MDSCs, a heterogeneous population of immature myeloid cells, induce
immunosuppression by causing defective T cell function (Fujimura, Mahnke et al.
2010). They classify into granulocytic-MDSCs (G-MDSCs; mouse: CD11b+Ly6G+;
human: CD11b+ CD15+) and monocytic (M-MDSCs; mouse: CD11b+Ly6C+;
human: CD11b+ CD14+) (Ostrand-Rosenberg and Sinha 2009, Goedegebuure,
B. Mitchem et al. 2011). In cancer patients, MDSCs have marked a systemic
expansion in the spleen, lymph nodes, and blood circulation, as well as at the
tumor sites (Gabrilovich and Nagaraj 2009).

These MDSCs can cause

immunosuppression at the tumor site by the production of nitric oxide synthase
(iNOS) and arginase 1 that suppress the proliferation and activation of T cells
(Nagaraj and Gabrilovich 2008, Gabrilovich and Nagaraj 2009, Fujimura, Mahnke
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et al. 2010, Goedegebuure, B. Mitchem et al. 2011). MDSCs can also suppress T
cells function in antigen-specific fashion via reactive oxygen species (ROS)
(Nagaraj and Gabrilovich 2008). Moreover, MDSCs promote the recruitment of T
regulatory lymphocytes (Tregs) to the tumor sites and blocking the entry of effector
T cells (Nagaraj and Gabrilovich 2008, Gabrilovich and Nagaraj 2009, Fujimura,
Mahnke et al. 2010, Goedegebuure, B. Mitchem et al. 2011).
CXCR2 axis has been implicated in the recruitment and expansion of
MDSCs. A report demonstrated that MDSCs reduction in tumor site was
accompanied with reduced CXCL5 protein expression (Weiss, Back et al. 2009).
Another report also indicated that CXCL1, 2 and 5 are responsible for the GMDSCs recruitment to the primary tumors (Toh, Wang et al. 2011). Furthermore,
colon cancer model exhibited high levels of CXCR2 ligands and the loss of CXCR2
diminished the G-MDSCs infiltration (Katoh, Wang et al. 2013). In PDAC, MDSCs
were shown to be present as early as the PanIN lesions and found further
increased infiltration in PDAC (Clark, Hingorani et al. 2007).

Using GEMM of

PDAC with both oncogenic Kras and p53 mutations, inhibiting CXCR2 reduced
MDSCs recruitment and improved response to immunotherapy (Steele, Karim et
al. 2016). Kumar et al. demonstrated that CAFs aid in recruiting MDSCs by
producing chemokines including CXCL1, 2 and 5 (Kumar, Donthireddy et al. 2017).
CXCR2 axis has been as well adversely implicated in enhancing
angiogenesis in many cancer types including lung, melanoma, and pancreas
(Matsuo, Ochi et al. 2009, Matsuo, Raimondo et al. 2009, Singh, Varney et al.
2009). The adverse role of CXCR2 in cancer has made it a hot target for inhibition.
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Multiple attempts to study the effect of CXCR2 inhibition have been completed. It
was

reported

that

inhibiting

CXCR2

suppressed

inflammation-driven

tumorigenesis in skin and intestine cancer models (Jamieson, Clarke et al. 2012).
In addition, using small interfering RNA, inhibiting CXCR1 and CXCR2 reduced
melanoma tumor growth and invasion (Singh, Sadanandam et al. 2010). For
PDAC, the pelleted supernatants from PDAC cell lines were injected into rat
corneal micropocket model, where blocking CXCR2 exhibited reduced
angiogenesis compared to supernatant injection alone (Wente, Keane et al. 2006).
Using Kras+Tgfbr2KO mice with conditional pancreas epithelium-TGF-β receptor
type II (Tgfbr2) knockout and Kras activation, inhibition of CXCR2 disrupted the
tumor-stromal interactions and improved mice survival by lowering the expression
of connective tissue growth factor (Ctgf) that promotes fibrosis and tumor
progression (Ijichi 2011). In another PDAC model, Steele et al. examined the effect
of CXCR2 inhibition in KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre) that
carries both pancreas-specific p53 mutation and oncogenic Kras. They concluded
that inhibiting CXCR2 suppresses metastasis, augments immunotherapy, and
improves survival by reducing MDSCs infiltration (Steele 2016). Furthermore, our
laboratory has generated a syngeneic CXCR2 knockout (Cxcr2-/-) model using KCderived cells. The CXCR2 stromal ablation caused no change to the tumor size
although it halted cancer cell proliferation and increased their apoptosis; it also
decreased the recruitment of MDSCs and increased the induction of cytotoxic T
lymphocytes re-orienting the tumor’s immune status towards an anti-tumor
immune response. On the other hand, depletion of CXCR2 increased fibrotic
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reaction within the primary tumor increased liver metastasis and increased the
abundance of tumor-associated macrophages (TAMs). The increased fibrosis
reveals a potential undescribed role of CXCR2 signaling in regulating CAFs in
PDAC (Purohit 2015).
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CANCER-ASSOCIATED FIBROBLASTS
Overview
PDAC is one of the leading causes of cancer-related deaths in the United
States. The late diagnosis, often after the disease has disseminated, and the
limited efficacy of the chemotherapy for advanced disease are the major
challenges in PDAC. Moreover, resistance to therapy and recurrence are frequent,
even for patients diagnosed with localized tumors (Siegel, Miller et al. 2018).
PDAC is highlighted with a dense and firm desmoplasia composed of ECM
deposition and infiltrating leukocytes, endothelial cells and CAFs (Kleeff, Beckhove
et al. 2007). Desmoplasia is implicated in PDAC development, progression,
dissemination as well as therapy resistance (Apte, Park et al. 2004, Moir, Mann et
al. 2015, Kalluri 2016). Resolving desmoplasia has been attempted through
digesting ECM, targeting CAFs or inhibiting desmoplasia-associated pathways
(Olive, Jacobetz et al. 2009, Provenzano, Cuevas et al. 2012, Özdemir,
Pentcheva-Hoang et al. 2014, Rhim, Oberstein et al. 2014). Some of these
attempts produced accelerated tumor progression and worsened prognosis
(Özdemir, Pentcheva-Hoang et al. 2014, Rhim, Oberstein et al. 2014), which
implies that there is more to desmoplasia than we currently know.
CAFs are the major contributor to desmoplasia, and they produce ECM and
multiple soluble factors that contribute to tumor progression (Apte and Wilson
2004, Omary, Lugea et al. 2007, Moir, Mann et al. 2015). Although CAFs are often
treated as a single entity, they are vastly heterogeneous by origin. There is an
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agreement that CAFs have a mesodermal origin, but their molecular definition is
still debatable. Currently, CAFs represent cells present in the tumor
microenvironment that are not tumor cells, leukocytes, endothelial, or epithelial
cells and that carry fibroblastic features such as the expression of fibroblastspecific protein 1 (FSP-1) (Öhlund, Elyada et al. 2014).
In PDAC, pancreatic stellate cells (PSCs) are the most studied CAFs
subtype. Stellate cells, referring to their star-like shape, are found in several organs
including the kidneys, lungs, intestines, spleen, uterus, and skin; but, they are
mainly described in liver and pancreas (Omary, Lugea et al. 2007, Apte, Wilson et
al. 2013, Öhlund, Elyada et al. 2014, Moir, Mann et al. 2015). PSCs are found in
the periacinar, perivascular or periductal regions of the exocrine pancreas. In
normal conditions, PSCs are usually in the quiescent state with long cytoplasmic
extensions and vitamin-A storing fat droplets. PSCs express many markers
including intermediate filament proteins desmin, and Glial fibrillary acidic protein
(GFAP) that along with Vitamin-A storing droplet can distinguish them from normal
fibroblast (Omary, Lugea et al. 2007, Apte, Wilson et al. 2013). PSCs markers
also characterize several other cell types such as desmin that is seen in
monocytes, GFAP of astrocytes, vimentin that also characterizes leukocytes and
endothelial cells, and Nestin of neuroepithelial stem cells (Omary, Lugea et al.
2007). Activation of PSCs occurs as a result of milieu changes such as pancreatic
injury or in response to secreted factors such as platelet-derived growth factor
(PDGF) and TGF-β (Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Moir,
Mann et al. 2015).

When activated, PSCs assume the myofibroblast-like,
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phenotype by upregulating α-smooth muscle actin (αSMA) and collagen I, and
losing their vitamin A-storing fat droplets in addition to increased nucleus size,
prominent ECM production, and increased cell proliferation and migration
potentials (Omary, Lugea et al. 2007, Erkan, Adler et al. 2012, Apte, Wilson et al.
2013, Moir, Mann et al. 2015). Additional reports indicated that activated PSCs
express fibroblast-activation protein α (FAP) (Bachem, Schünemann et al. 2005,
Apte, Wilson et al. 2013, Moir, Mann et al. 2015). Activated PSCs play essential
roles in pancreatic repair following injury and acute inflammation via modulating
ECM production and tissue remodeling (Omary, Lugea et al. 2007, Apte, Wilson
et al. 2013). Following the secession of the pancreatic assault, activated PSCs
revert into quiescence or undergo apoptosis. Repeated assaults and chronic
pancreatic inflammation cause sustained PSCs activation, which increases the risk
of fibrosis and cancer (Omary, Lugea et al. 2007, Apte, Pirola et al. 2015).
Tissue-resident fibroblasts can also contribute to CAFs population (Öhlund,
Elyada et al. 2014). A subset of normal fibroblasts was found to express the
glycoprotein Thy-1 was able to differentiate into CAFs after treatment with TGF-β.
Genetic mutations such as inactivation of p53 and PTEN has been frequently
observed in stromal cells and can also turn them into CAFs (Xing, Saidou et al.
2010). Moreover, CAFs can arise by transdifferentiating through EMT or
endothelial to mesenchymal transition (Xing, Saidou et al. 2010, Öhlund, Elyada
et al. 2014), but more direct sources of CAFs include bone marrow-derived
fibrocytes, mesenchymal stem cells, and adipocytes (Xing, Saidou et al. 2010,
Öhlund, Elyada et al. 2014). These diverse origins of CAFs can explain the
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absence of consensus on a molecular definition. Nonetheless, multiple markers
have been widely used to distinguish CAFs including PDGF-receptor-β (PDGFRβ), αSMA and FAP (Bachem, Schünemann et al. 2005, Apte, Wilson et al. 2013,
Moir, Mann et al. 2015). These markers are not uniformly expressed in all CAFs
(Öhlund, Elyada et al. 2014), which can be due to the presence of CAFs
concurrently at multiple differentiation stages or because of the diverse origins of
CAFs. The coexistence of multiple subsets of CAFs could explain the diverse roles
and abilities they carry out to promote tumorigenesis and progression and could
explain why targeting CAFs using a single marker, such as αSMA, can have an
adverse outcome (Özdemir, Pentcheva-Hoang et al. 2014). CAFs have been
described to be versatile and to have a wide range of roles in cancer (Omary,
Lugea et al. 2007). It is not clear however if all the roles can be carried out by all
CAFs or the versatility is due to CAFs diversity. A better understanding of different
CAFs subsets could greatly impact our ability to target desmoplasia safely. In this
section, we will discuss the functional heterogeneity of CAFs and how the
abundance of specific subsets can influence tumor progression or lack thereof.
Role of CAFs in PDAC
PDAC develops as a result of a progressive accumulation of genetic
alterations in multiple oncogenes and tumor suppressor genes. Oncogenic Kras
occur very early preceding PDAC precursors. The late events of inactivating tumor
suppressors such as p53 and Smad4 allow progression to invasive PDAC (Maitra
and Hruban 2008, Hidalgo 2010, Vincent, Herman et al. 2011). Although mutations
are essential for the malignancy, they do not render them autonomous. Numerous
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survival, growth, and invasion cues are obtained through cellular and molecular
interactions with other components in the tumor microenvironment. CAFs have
been implicated in multiple hallmarks of cancer including sustained proliferative
signaling, tumor-promoting inflammation, and invasion and metastasis (Kleeff,
Beckhove et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015). In some
cancers, the accumulation of CAFs and ECM changes were observed prior to
tumor formation, which indicates that CAFs recruitment is essential for tumor
development and maybe a prerequisite (DeFilippis, Chang et al. 2012, Sasaki,
Baba et al. 2014, Ghosh, Vierkant et al. 2017).

The most notable adverse

contribution of CAFs to the tumor is acting both physically and biochemically to
hinder drug delivery and impose resistance. CAFs produce ECM molecules such
as collagen, fibronectin, and hyaluronan (Bachem, Schünemann et al. 2005,
Nikitovic, Tzardi et al. 2015). The increased deposition of such molecules
physically impairs drug delivery to the tumor (Jacobetz, Chan et al. 2012,
Provenzano and Hingorani 2013). Inhibiting the Hedgehog (HH) pathway, a major
promotor of desmoplasia, and using enzymatic digestion of desmoplasia facilitated
drug delivery and increased the intratumoral concentration of the chemotherapy
agent (Olive, Jacobetz et al. 2009, Provenzano, Cuevas et al. 2012). Moreover,
factors secreted by CAFs such as hepatocyte growth factor (HGF), interleukin (IL)6 and CXCL8 have been implicated in therapy resistance either by activating
resistance-associated pathways or inducing stemness in tumor cells (Omary,
Lugea et al. 2007, Garrido-Laguna, Uson et al. 2011, Straussman, Morikawa et al.
2012, Chan, Hsu et al. 2016, Su, Chen et al. 2018).
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CAFs are also tied to PDAC metastasis. Increased tumor stiffness as a
result of increased ECM depositions, can increase tumor cells contractility, thus
allowing tumor cell detachment and invasion (Ahmadzadeh, Webster et al. 2017).
Biochemically, CAFs can play a role in up-regulating EMT that endows tumor cells
with more migratory and invasion potentials. Tumor cells co-cultured with CAFs
had

a

fibroblast-like

appearance,

increased

migration

and

expressed

mesenchymal markers Vimentin, Snail-1 and Zeb (Kikuta, Masamune et al. 2010).
One proposed mechanism for CAFs-induced EMT involves TGF-β that is highly
produced by myofibroblasts (Shek, Benyon et al. 2002, Shek, Fmj et al. 2002).
CAFs involvement in PDAC also extends to tumor growth, proliferation and
nourishment as well as immunosuppression and immune evasion (Apte, Wilson et
al. 2013, Moir, Mann et al. 2015, Bynigeri, Jakkampudi et al. 2017). But, is targeting
desmoplasia or CAFs a solution for resolving PDAC aggressiveness? There are
conflicting reports on usefulness of targeting CAFs. Olive et al. observed increased
vascularization, and improved drug delivery as well as decreased αSMA cells and
improved the overall survival of the test mice in response to an inhibitor that targets
the HH pathway (Olive, Jacobetz et al. 2009). The drug, however, when put into
the test in a clinical trial rendered a decreased survival. Ozdemir et al. developed
a mice model that is depleted of αSMA cells. This model demonstrated an
accelerated PDAC with reduced survival, undifferentiated tumors, increased
chemotherapy

resistance,

stemness,

and

immunosuppression

(Özdemir,

Pentcheva-Hoang et al. 2014). Rhim et al. targeted desmoplasia by inhibiting the
HH pathway. In this model, PDAC exhibited tumors with undifferentiated histology,
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increased vascularity and proliferation, and reduced survival and myofibroblast
infiltration (Rhim, Oberstein et al. 2014). Together, these independent experiments
demonstrate that inhibiting myofibroblasts results in aggressive PDAC with intense
immunosuppression, heightened proliferation, tumor stemness, and therapy
resistance.
We have discussed the heterogeneity of CAFs based on their origin;
however, it is not clear if they present with functional diversity within the tumor and
if their origin impacts their function. Ohlund et al. described a distinct subset of
CAFs in PDAC with a secretory function that is different from the typical
myofibroblast CAFs (Ohlund, Handly-Santana et al. 2017). These newly described
CAFs are characterized with increased secretion of inflammatory mediators,
particularly IL-6, and decreased expression of αSMA in addition to their ability to
promote tumor cells proliferation (Ohlund, Handly-Santana et al. 2017). Thus,
CAFs heterogeneity in PDAC can explain why particularly targeting myofibroblasts
can render a more adverse outcome. It is not clear at this point if other functional
subsets, other than myofibroblasts and secretory CAFs, present. In the next
sections, we will discuss the contexts by which myofibroblasts or secretory CAFs
develop and their impact on the tumor outcome.
Myofibroblast CAFs
Overview
For long, CAFs and myofibroblasts were considered synonymous in the
context of cancer and often used interchangeably. We know now that is not
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accurate. Besides cancer, myofibroblasts are often described in the context of
wound healing, in which quiescent fibrotic cells get activated to undertake tissue
repair and remodeling. Cancers are often referred to as “wounds that do not heal”
(Dvorak 1986). Looking into the wound healing process can provide insights into
the dynamics of CAFs activity in cancer.
Wound healing
Tissue injury causes plasma leakage from local blood vessels. Shortly after,
extravasated plasma initiates wound sealing by forming a clot of fibrin, fibronectin,
and platelets to trap the blood inside. The sealant clot acts as a provisional scaffold
for the migration of inflammatory cells recruited through factors secreted from the
damaged tissue cells as well as the platelets. Inflammatory cells clear debris,
infectious agents and degrade the clot. Next, activated fibroblasts form granulation
tissue by depositing ECM molecules such as collagen, glycosaminoglycans, and
fibronectin. Fibroblasts also enable vascularization by recruiting and modulating
endothelial cells. Finally, before they disappear, fibroblasts remodel the
granulation tissue allowing few blood vessels and dispersed fibrocytes in the dense
collagenous scar that replaced the collapsed tissue (Dvorak 1986, Midwood,
Williams et al. 2004). As it appears, wound healing is a very coordinated process.
First platelets modulate, provisionally, sealing the wound and recruiting
inflammatory cells. Next, neutrophils then macrophages clean the mess before
allowing fibroblasts to generate the permanent sealant. Cytokines and chemokines
coordinate the timely recruitment and activation of different cells.
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Interestingly, ECM deposition and remodeling by fibroblasts occurs after the
secession of inflammation (Midwood, Williams et al. 2004). Inflammation during
wound healing, in particular neutrophils and macrophages, happens in two phases.
Neutrophils are among the first responders, recruited mainly through CXCR1/2, to
clear the infectious aggressors (Wu, Wang et al. 2011, de Oliveira, Rosowski et al.
2016). Classically activated macrophages (M1) are known pro-inflammatory cells
that ingest and degrade tissue debris, pathogens, retired neutrophils, and ECM
scaffold to set the stage for tissue repair. Alternatively activated macrophages (M2;
the pro-repair and the anti-inflammatory counterparts of M1) produce cytokines
that dampen the inflammation including IL-10 and TGF-β (Wynn and Barron 2010,
Xue, Sharma et al. 2015, Wynn and Vannella 2016). The latter is known to activate
myofibroblasts and induce ECM deposition and remodeling (Midwood, Williams et
al. 2004, Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al.
2015), the last step in tissue repair. Fibroblasts in wound healing are mainly
described as myofibroblasts that are responsible for ECM deposition and
remodeling, but it is not clear if other subsets of fibroblasts present with distinct
roles similar to those found in cancer that amplifies inflammation.
The context of myofibroblasts in PDAC
Several secreted mediators, such as PDGF and TGF-β, are considered to
have ties to the development of myofibroblasts from quiescent fibrotic cells
(Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015). TGFβ typically signals through the Smad pathway. Smad4, also known as DPC4,
which is commonly inactivated in PDAC (Ahmed, Bradshaw et al. 2017). TGF-β,
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produced by macrophages, lymphocytes, fibroblasts, epithelial cells, and platelets
(Blobe, Schiemann et al. 2000, Massagué 2012), is essential in prenatal and
postnatal development, organ maintenance and homeostasis, and wound healing
(Blobe, Schiemann et al. 2000, Massagué 2012). Intact TGF-β/Smad4 signaling
works as a tumor suppressor (Blobe, Schiemann et al. 2000, Massagué 2008,
Massagué 2012); however, Smad4 inactivation results in ligand accumulation that
signal in tumor cells through Smad-independent pathways to mediate EMT,
cytoskeletal organization and motility (Massagué 2008, Ahmed, Bradshaw et al.
2017). In fibroblasts, TGF-β is known to induce activation and ECM deposition,
inhibit MMPs synthesis causing stiffness (Shek, Fmj et al. 2002). In PDAC,
elevated TGF-β levels regulates EMT and tumor stiffness, and correlates with
metastasis and poor survival (Liu, Pouponnot et al. 1997, Tascilar, Skinner et al.
2001, Tang, Katuri et al. 2005, Massagué 2008, Blackford, Serrano et al. 2009,
Zhang 2009, Singh, Srinivasan et al. 2012, Xia, Wu et al. 2014, Ahmed, Bradshaw
et al. 2017).
Another molecule that has been linked to myofibroblasts is PDGF. Many
reports tie PDGF to fibroblasts activation and ECM synthesis along with TGF-β;
however, the effect of PDGF is not the same as TGF-β (Omary, Lugea et al. 2007,
Apte, Wilson et al. 2013). Besides enhancing the proliferation of activated
fibroblasts, PDGF plays a significant role in blood vessel formation and
maintenance (Forsberg, Valyi-Nagy et al. 1993, Crawford, Kasman et al. 2009).
PDGF is mainly secreted by activated platelets but can also be produced by other
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cells such as macrophages and endothelial cells (Forsberg, Valyi-Nagy et al. 1993,
Crawford, Kasman et al. 2009, Hammer, Sizemore et al. 2017).
HH molecules, including sonic (SHH), Indian and desert-HH, are
morphogens that play a crucial role in embryologic growth and tissue
morphogenesis. SHH is implicated in wound healing and repair (Kayed, Kleeff et
al. 2006, Le, Kleinerman et al. 2008). In cancer, SHH is highly implicated in
desmoplasia and disrupting HH pathway was shown to reduce myofibroblasts
(αSMA+ cells), reduce ECM deposition and enhance angiogenesis and drug
delivery (Bailey, Swanson et al. 2008, Bailey, Mohr et al. 2009, Olive, Jacobetz et
al. 2009, Tian, Callahan et al. 2009, Smelkinson 2017) (Rhim, Oberstein et al.
2014). Several other molecules have been linked to fibroblasts activation;
however, there is not enough evidence to connect them to a certain CAFs subset.
In summary, several molecules, including TGF-β, PDGF and SHH,
cooperate to establish and maintain desmoplasia by promoting myofibroblastsphenotype in CAFs. The abundance of myofibroblasts is associated with ECM
synthesis and deposition, tumor stiffness, EMT augmentation, and invasion and
metastasis.
Secretory CAFs
Overview
Ohlund et al. identified the presence of two distinct phenotypes of CAFs in
PDAC. The typical myofibroblasts (αSMA high) with high ECM synthesis were
found adjacent to the tumor cells. The other phenotype that they referred to as
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inflammatory CAFs (αSMA low) found at a distance from tumor cells and had a
lower ECM expression and a higher expression of inflammatory mediators, in
particular, IL-6. Inflammatory CAFs possessed the ability to induce tumor cell
proliferation (Ohlund, Handly-Santana et al. 2017).
It is established that CAFs secreted several paracrine factors to modulate
both inflammatory and fibrotic processes (Omary, Lugea et al. 2007, Moir, Mann
et al. 2015). This, however, was attributed to the plasticity and versatility of CAFs
and to their ability to carry out multiple roles at the same time. The notion of
specialized CAFs subsets is fairly recent and largely understudied. Nonetheless,
several reports have pointed, without directly concluding, towards the ability of
CAFs to be secretory in certain contexts. We will first discuss the relationship
between inflammation and CAFs.
CAFs and inflammation
Extensive studies of pancreatic inflammation shown that CAFs express
several paracrine factors and their receptors, which modulates inflammatory and
fibrotic processes. Inflammation and fibroblasts activity are closely linked. In
pancreatitis, for instance, damage in pancreatic tissues proceeds a succession of
events including interstitial edema, parenchymal cells necrosis, trypsin activation,
inflammatory cell infiltration, and lastly the activation and proliferation of PSCs
(Omary, Lugea et al. 2007). The activated PSCs are often found in areas rich in
cytokines, growth factors, and reactive oxygen species such as near necrotic
tissues (Omary, Lugea et al. 2007). The excessive ECM deposition and
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remodeling that follows PSCs activation is likely a late step in the tissue repair
process similar to that seen in wound healing.
CAFs actively contribute to inflammation by producing several cytokines
and chemokines. Besides PDGF and TGF-β that are well recognized in their
fibrogenic roles, CAFs secrete several factors including IL-1β, IL-4, IL-6, IL-8, IL13, vascular endothelial growth factor (VEGF) and many others (Omary, Lugea et
al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015).

These factors

contribute to cancer progression by providing means for inflammation,
immunosuppression, tumor cells proliferation, angiogenesis, and chemotherapy
resistance (Apte, Wilson et al. 2013, Moir, Mann et al. 2015).
As we discussed in wound healing, activated fibroblasts only proceed to
ECM deposition after the secession of inflammation, which may suggest that
inflammation acts as a checkpoint that regulates fibroblasts differentiation into
myofibroblasts. This is also similar to the activated PSCs during pancreatitis
(Omary, Lugea et al. 2007). It is not clear though if a secretory (or inflammatory)
phenotype present during these processes.
The context of secretory CAFs
Ohlund et al. described the secretory (inflammatory) CAFs as they develop
when they do not have adjacency to the tumor cells (Ohlund, Handly-Santana et
al. 2017). This may implicate far-reaching paracrine factors such as chemokines.
There is not enough evidence though to conclude on the exact mechanism by
which secretory CAFs develop (Ohlund, Handly-Santana et al. 2017). We will next
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discuss a few reports that have indicated secretory functions in CAFs, and we will
aim to identify the common denominator that can explain the development of the
secretory CAFs.
Chan et al. treated CAFs of breast cancer and PDAC with the maximumtolerated dose of chemotherapy (Chan, Hsu et al. 2016). The treatment caused
CAFs to undergo senescence, activate transcription factors such as the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the signal
transducer and activator of transcription 1 (STAT1), and highly express a group of
chemokines that signal through the chemokine receptor CXCR1/2 axis (Chan, Hsu
et al. 2016). These secreted factors enhanced tumor cell proliferation and
stemness, angiogenesis, recruitment of MDSCs, and rendered larger tumors
(Chan, Hsu et al. 2016).

Senescence often happens in response to the

accumulation of somatic mutations, oxidative stress, telomere dysfunction and
shortening, loss of immune surveillance, and chronic inflammation in response to
inflammatory mediators such as IL-1β, IL-6, and IL-8 (Campisi and d'Adda di
Fagagna 2007, Acosta, O'Loghlen et al. 2008, Kuilman, Michaloglou et al. 2010).
Senescence in CAFs has been reported on multiple occasions to impact
tumorigenicity and tumor cells behaviors (Collado, Gil et al. 2005, Cichowski and
Hahn 2008, Hinds and Pietruska 2017). Senescent fibroblasts promoted
proliferation and altered epithelial cell differentiation in breast cancer (Parrinello
2005). Bavic et al. showed that senescent CAFs of prostate cancer promote
proliferation of tumor cells through paracrine signaling (Bavik, Coleman et al.
2006). Wang et al. reported that senescent CAFs upregulate CXCL8 and enhance
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tumor cells migration and invasion (Wang, Notta et al. 2017). Lastly, the induction
of CAFs senescence generates a non-fibrogenic myofibroblast phenotype with
lower ECM synthesis (Mellone, Hanley et al. 2016). Although it seems convincing,
senescence cannot account for it all. According to Ohlund et al., tumor cells also
promoted the proliferation of the secretory phenotype indicating that they are not
senescent (Ohlund, Handly-Santana et al. 2017).
Nonetheless, one common feature of senescent cells is that they activate
transcription factors, such as NF-κB and STAT1, that upregulate several paracrine
including IL-1β, IL-6, CXCL8, and VEGF (Salminen, Kauppinen et al. 2012, Chan,
Hsu et al. 2016, Korc 2016, Lesina, Wormann et al. 2016). NF-κB, in particular,
has been under a lot of scrutinies in inflammatory diseases and cancers (Korc
2016, 2017). NF-κB is highly associated with inflammation. Inflammation triggers
NF-κB activation, which in turn further amplifies inflammation. Acute inflammation
triggered by several factors including cytokines, chemokines, pathogen-associated
molecular patterns, and damage-associated molecular patterns (DAMPs)
(DiDonato, Mercurio et al. 2012). A recent report by Su et al. indicated that
complement components could signal through the G protein-coupled receptor 77
(GPR77) on CAFs of breast and lung cancers to activate NF-κB, which result in
upregulation of IL-6 and CXCL8 that promote stemness in tumor cells and cause
chemotherapy resistance (Su, Chen et al. 2018). Although the authors could not
observe a downregulation in the αSMA or the ECM production, they identified this
secretory subset of CAFs using GPR77 and cluster of differentiation 10 (CD10) as
surface markers (Su, Chen et al. 2018). CD10 is a small metalloprotease that is
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also known as common acute lymphoblastic leukemia antigen (CALLA), where it
used as a prognostic marker (Maguer-Satta, Besancon et al. 2011). CD10+
stromal cells have been identified in several cancers including colorectal cancer
(Ogawa, Iwaya et al. 2002), breast cancer (Iwaya, Ogawa et al. 2002), gastric
cancer (Huang 2005), and PDAC (Ikenaga, Ohuchida et al. 2010). In PDAC,
CD10+ CAFs promoted tumor cells growth and invasion and was associated with
reduced survival and nodal metastasis (Ikenaga, Ohuchida et al. 2010). It is not
clear at this point if CD10 is uniformly expressed in all secretory CAFs or not.
CXCL8, also known as IL-8, is a chemokine that signals via CXCR1/2 axis
along with a group of angiogenic chemokines including CXCL1-3 and CXCL5-8,
known as ELR+ chemokines referencing the conserved amino acids motif of GluLeu-Arg. ELR+ chemokines are known chemoattractant of myeloid cells such as
neutrophils and MDSCs (Vandercappellen, Van Damme et al. 2008, Zlotnik and
Yoshie 2012). For that, CXCR2 axis is often considered pro-tumorigenic in many
cancers (Bizzarri, Beccari et al. 2006, Strieter, Burdick et al. 2006). In PDAC
CXCR2 axis is involved in MDSCs recruitment, angiogenesis, tumor cells
proliferation and migration. Upregulation of CXCR2-axis in PDAC is associated
with tumor-supporting inflammation, immunosuppression, angiogenesis and tumor
growth. This has made CXCR2 a hot target for PDAC therapy (Vandercappellen,
Van Damme et al. 2008, Chao, Furth et al. 2016, Purohit, Varney et al. 2016). The
CXCR2 axis adverse role in PDAC was more apparent in line with the oncogenic
Kras mutation (Purohit 2015, Purohit, Varney et al. 2016). Purohit et al. generated
a syngeneic Cxcr2-/- model using PDAC cells with oncogenic Kras. This stromal
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ablation of CXCR2 inhibited tumor growth, reduced immunosuppression by
lowering infiltration of MDSCs, reduced angiogenesis, but also increased the
fibrotic reaction in the primary tumor and increased metastasis. The increased
fibrosis in response to CXCR2 inhibition suggests that CXCR2 axis may play a role
in regulating CAFs (Purohit 2015). It is known that CAFs secrete CXCL8 (Omary,
Lugea et al. 2007); but, little is known about the role of CXCR2 in CAFs. Few
reports have linked CXCR2 to the stromal compartment in PDAC. Inhibiting
CXCR2 in the genetically engineered PDAC mouse model that carries oncogenic
Kras mutation and TGF-β receptor knockout disrupted the tumor-stromal
interactions and improved mice survival (Ijichi, Chytil et al. 2011). Steele et al. used
a mouse model with oncogenic Kras and p53 mutations and concluded that
CXCR2 is abundant in the stromal regions and that inhibiting CXCR2 suppresses
metastasis, and improves survival by reducing MDSCs infiltration, although the
author did not elaborate on the effect of CXCR2 inhibition on CAFs (Steele, Karim
et al. 2016).
The proposed role of CXCR2 axis in CAFs goes along with what Ohlund et
al. reported that the secretory CAFs develop at a distance from tumor cells
(Ohlund, Handly-Santana et al. 2017). ELR+, as well as other chemokines, are
considered far-reaching compared to other cytokines such as TGF-β. Chemokines
make gradients to recruit target cells from distant locations such as the circulation
or the bone marrow, whereas the effect of cytokines is often local. CXCR2 axis is
also known to activate NF-κB, and the sustained CXCR2 signaling was even
implicated in the induction of senescence (Acosta, O'Loghlen et al. 2008, Acosta,
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O'Loghlen et al. 2008, Acosta and Gil 2009, Cavalli, Biavasco et al. 2014, Lesina,
Wormann et al. 2016). Overall, we believe that secretory CAFs develop in the
context of inflammation. Inflammatory mediators such as ELR+ chemokines and
DAMPs activate inflammatory pathways including NF-κB and STAT1 and render
CAFs secretory.
The proposed role secretory CAFs in PDAC
Secretory CAFs produce several paracrine factors including interleukins,
chemokines and growth factors such as VEGF (Omary, Lugea et al. 2007, Moir,
Mann et al. 2015). The factors with more consensus include IL-6 and CXCL8,
among other ELR+ chemokines. The secreted factors produced by CAFs have
been implicated in multiple pro-tumorigenic events including tumor cells
proliferation and migration, stemness, immunosuppression, chemotherapy
resistance, and invasion; however, some of these events lack consensus. The
roles of IL-6 and CXCL8 in cancer is often associated with increased tumor cells
proliferation, recruitment of MDSCs, angiogenesis, tumor cells stemness (Singh,
Varney et al. 2009, Purohit 2015, Chan, Hsu et al. 2016, Purohit, Varney et al.
2016, Steele, Karim et al. 2016, Su, Chen et al. 2018). Thus, we expect to find out
that tumors with abundance in secretory CAFs to be bigger in volume due to
proliferation cues and vascularity, immunosuppressive due to MDSCs infiltration,
and resistant to chemotherapy with enhanced undifferentiated histology as a result
of stemness. On the other hand, the abundance of myofibroblast will likely result
in increased stiffness, hypoxia, induction of EMT, infiltration of macrophages and
metastasis. Such characteristics observed with stromal CXCR2 deletion.
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CONCLUSION
PDAC remains one of the most challenging human malignancies due to its
late detection and low effectiveness of current therapies. The characteristic
complex tumor microenvironment and the dense desmoplastic reaction in PDAC
contribute to tumorigenicity and tumor progression. CAFs represent a major
component in PDAC tumor microenvironment and contribute to tumor progression
and dissemination. Based on the information available in the literature, we
discussed the role of genetic alterations in PDAC development, the impact of
inflammation and secreted mediators on tumor progression, the CAFs
heterogeneity effect on tumor outcome. We gathered thus far, oncogenic Kras
derives tumorigenesis and contribute inflammation by upregulating CXCR2 axis.
CXCR2 signaling promotes tumor growth, immunosuppression, and angiogenesis.
There are at least two functional entities within the CAFs population.
Myofibroblasts, the typical CAFs are characterized by enhanced ECM production
and the expression of αSMA; whereas, the secretory CAFs propagates
inflammation by secreting mediators such as IL-6 and ELR+ chemokines. We
believe that oncogenic Kras-CXCR2 axis promotes the secretory CAFs and that
the abundance of certain CAFs subtype could impact the tumor outcome.
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HYPOTHESIS AND SPECIFIC AIMS
PDAC remains one of the most challenging human malignancies due to its
late detection and low effectiveness of current therapies. The characteristic
complex tumor microenvironment and the dense desmoplastic reaction in PDAC
contribute to tumorigenicity and tumor progression. CAFs represent a major
component in PDAC tumor microenvironment and contribute to tumor progression
and dissemination. Based on the information available in the literature, we
discussed the role of genetic alterations in PDAC development, the impact of
inflammation and secreted mediators on tumor progression, the CAFs
heterogeneity effect on tumor outcome. We gathered thus far, oncogenic Kras
derives tumorigenesis and contribute inflammation by upregulating CXCR2 axis.
CXCR2 signaling promotes tumor growth, immunosuppression, and angiogenesis.
There are at least two functional entities within the CAFs population.
Myofibroblasts, the typical CAFs are characterized by enhanced ECM production
and the expression of αSMA; whereas, the secretory CAFs propagates
inflammation by secreting mediators such as IL-6 and ELR+ chemokines. We
believe that oncogenic Kras-CXCR2 axis promotes the secretory CAFs and that
the abundance of certain CAFs subtype could impact the tumor outcome.
Based on that, our central hypothesis for this project is that: oncogenic KrasCXCR2 axis modulates the CAFs function and activity and thus impacts PDAC
outcome.
Specific Aims
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To test our hypothesis, I pursued the following specific aims.
Specific Aim 1: Define the role of oncogenic Kras-CXCR2 axis in CAFs function and
activity in PDAC.
Specific Aim 2: Evaluate the CXCR2-dependent role of CAFs in PDAC.
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Figure 1.1: Stromal infiltration in human PDAC
Microscopic images that show the extent of CAFs infiltration in human PDAC
sections stained with H&E (left) or the CAFs marker FAP (right).
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Figure 1.2: Depiction of the hypothesized CXCR2-dependent role of CAFs
in PDAC.
Oncogenic Kras-CXCR2 axis modulates the CAFs function and activity and thus
impacts PDAC outcome.

47

CHAPTER II: MATERIALS AND METHODS
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CELL LINE CULTURES
Cell lines and culture conditions
Murine cell lines
PDAC murine cells Panc02 cells and UN-KC-6141 cell line (referred to in
this study as KC), and the immortalized mouse pancreatic stellate cells (ImPSC),
were a kind gift from Dr. Surinder K. Batra’s laboratory at UNMC. Panc02 were
maintained in Roswell Park Memorial Institute Medium (RPMI) (HyClone®, GE Life
Sciences, UT), and KC along with ImPSC cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) (HyClone®, Thermo Scientific, UT). These media
were supplemented with 5% fetal bovine serum (FBS) (Atlanta Biologicals, GA), Lglutamine (MediaTech, VA), twofold vitamin solution (MediaTech) and gentamycin
(Gibco, Life Technologies, NY).
Human cell lines
CAF cell lines: Immortalized human CAF cell line (10-32 PC Puro, a kind
gift from Dr. Surinder K. Batra’s laboratory at UNMC) was maintained in RPMI
media supplemented with 5% FBS, L-Glutamine, twofold vitamin solution,
gentamycin and 5 μg/mL of puromycin Dihydrochloride (Herndon, VA). Normal
human fibroblast, BJ cell line, was obtained from ATCC was maintained in Eagle's
Minimum Essential Medium (EMEM; Cellgro, Herndon, VA) supplemented with
10% FBS, streptomycin, and penicillin. Immortalized human CAFs (CAF; a kind
gift from Dr. Surinder K. Batra’s laboratory at UNMC) was derived from the
pancreatic tumor tissues. The pancreatic tumor was minced, and fibroblasts were
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isolated by differential trypsinization, which was subsequently immortalized using
hTERT. It was then maintained in EMEM supplemented with 10% FBS,
streptomycin, and penicillin.
HPNE and HPNE-Kras: Immortalized human pancreatic duct-derived cell
lines that express exogenous KRAS(G12D) (HPNE-Kras) or normally express
wildtype Kras (HPNE) (Campbell, Groehler et al. 2007) were maintained in special
media consisted of three parts DMEM (HyClone®, Thermo Scientific, UT) and one
part in M3:5 growth medium (INCELL, San Antonio, TX) supplemented with 5%
FBS, L-glutamine, twofold vitamin solution and gentamycin.
PDAC human cell lines: HPAF was maintained in RPMI 1640 supplemented
with 5% FBS, L-glutamine, twofold vitamin solution and gentamycin. HPAF-CD11
were in DMEM supplemented with 10% FBS, L-glutamine, twofold vitamin solution
and gentamycin. The previously described CD18/HPAF cell lines that was either
transfected with KRAS(G12D) knockdown vector (CD18/HPAF-Kras KD) or control
vector (CD18/HPAF-scram) (Rachagani, Senapati et al. 2011) were maintained in
DMEM

supplemented with 5% FBS, L-Glutamine, twofold vitamin solution,

Gentamycin and 5 μg/mL of puromycin Dihydrochloride.
Generation of conditioned media
Cells were cultured in their respective complete media for 24h at density of
1x105 cells per well in a six-well plate, then media was removed, cells washed with
Hanks’s balanced salt solution (HBSS, Cellgro, Herndon, VA) and the media was
changed to serum-free media for 24h or 72h.
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Generation of ECM from CAFs
We used the methods established by (Mizuguchi, Utoguchi et al. 1997).
Briefly, we seeded CAFs cell (1x105 cells) onto six-well plate and culture them with
complete media. After the CAFs cell reach confluence (~24 hours later), we
removed the media and washed the cells once with PBS, and then added 1ml of
the aqueous solution of 0.02N ammonia to the cells, and incubated them at room
temperature for 10 min to lyse the cells. We removed any remaining cellular debris
from the culture plate by gentle pipetting and washed the resulting lysate over ten
times HBSS.
Co-culture using conditioned media and treatment with exogenous
chemokines and inhibitor
Cells were seeded at a density of 1x105 cells/well using six-well plates and
maintained in complete media for 24h. Complete media was replaced with serumfree media, diluted conditioned media, or respective treatment and incubated for
the respective time.
Co-culture using CAF monolayer or ECM
To generate CAF monolayer, 1x106 cells of CAFs were seeded in the sixwell plate and incubated with complete media for 24 hours. Pancreatic cancer cells
at a density of 1x105 were then seeded onto the CAFs monolayer or the CAFs
ECM and co-cultured in complete media. After a 24-hour incubation, complete
media was changed to serum-free media (day 0) and incubated for an additional
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72h (day 4). We counted the number of tumor cell and calculated the differences
between Day 0 and Day 4.
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ANIMAL MODEL AND DETAILS OF IN VIVO STUDIES
Study approval
Mice were maintained under specific pathogen-free conditions. All
procedures performed were in accordance with institutional guidelines and
approved by the University of Nebraska Medical Center Institutional Animal Care
and Use Committee (IACUC).
Syngeneic mouse models
We utilized two models of a syngeneic immunocompetent mouse model to
study the effect of Kras mutation and stromal CXCR2 signaling on the tumor. Two
different murine PC cell lines Panc02-GLUC-GFP (wildtype Kras; contains a single
nucleotide polymorphism in Kras gene from TAT to TAC at codon 32) (Wang,
Zhang et al. 2012) and KRAS-PDAC-GFP (oncogenic Kras) (Purohit, Varney et al.
2016), were inoculated orthotopically in the pancreas of 6-8 weeks old CXCR2+/+
(Wildtype) and CXCR2-/- (knockout) mice. Mice were sacrificed after 4-6 weeks as
previously described (Purohit 2015). A part of the tumor was fixed in 10% formalin
and processed for histological analysis.
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REAGENTS AND ANTIBODIES
CXCR2 inhibitors SCH-479833 and SCH-527123, obtained from ScheringPlough Research Institute, and prepared by dissolving in 20% hydroxypropyl-βcyclodextrin (HPβCD; Acros Chemical St. Louis, MO). Exogenous human CXCL8
and exogenous murine CXCL1 were obtained from (R & D Systems, Minneapolis,
MN, USA). A list of all the antibodies used for the present study is available in Table
2.1.
GENE EXPRESSION ANALYSIS
RNA isolation
Total RNA was isolated from cells and homogenized tissues using the
standard Trizol (Invitrogen, Carlsbad, CA) protocol. Briefly, cells were lysed with 1
ml of Trizol followed by adding 0.2 ml of chloroform and vigorous shaking. After 23 min incubation, the mixture was separated by centrifugation at 12,000 g for 15
min. The aqueous phase was then transferred and mixed with 750 µl of
isopropanol and incubated in the rotator for 10 min. Tubes were then centrifuged
at 12,000 g for 10 min, and the supernatant was discarded. The pellet was washed
with 75% ethanol, air dried and eluted in DEPC-treated water.
PCR analysis
Reverse Transcription was performed with 1μg RNA using iScript™
Reverse Transcription Supermix for qRT-PCR (BIO-RAD, Hercules, CA, USA).
Regular PCR reactions were performed using Fast Start Taq dNTPack (Roche
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Diagnostics, IN, USA). Quantitative real-time PCR reactions were performed using
iTaq Universal SYBR Green Supermix (BIO-RAD, Hercules, CA, USA) using the
CFX Connect™ Real-Time PCR Detection System (BIO-RAD). Primer sets used
for the study are listed in Table 2.2. For regular PCR, amplified cDNA was resolved
on EtBr containing 2% agarose gels. For real-time PCR mean Ct values of the
target genes were normalized to mean Ct values of one or more the housekeeping
control genes (Ribosomal protein large 13 A (RPL13A), β Actin, Peptidylprolyl
Isomerase A (PPIA) and Hypoxanthine phosphoribosyltransferase 1 (HPRT1)); [ΔCt = Ct (housekeeping gene) – Ct (target gene)]. The ratio of mRNA expression
of target genes versus the housekeeping gene was defined as 2(-ΔCt). Melting
curve analysis was performed to check the specificity of the amplified product.
Gene expression microarray
PDAC cell lines HPAF and HPAF-CD11 were cultured alone or on CAF
monolayer. Next, nucleic acid was collected for cDNA microarray analysis using a
set of two 10K chips (Compugn/Sigma Genosys) that interrogate the full 18+
Compugen Human oligonucleotide at DNA Microarray core facility (UNMC). The
library contains 18,861 oligos representing 17,260 unique genes. Raw fluorescent
intensity values were collected to determine gene expression levels. Flagged
artifacts and negative controls were removed from the series. The data was then
normalized, and the channels (Cy3 and Cy5) were background subtracted. The
normalized and background subtracted values were log2 transformed. The foldchange was calculated between the Cy3 and Cy5 channels. Emphasis was placed
on genes demonstrating greater than 2 fold-change in expression between the two
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channels. A list of 169 chemokines and cytokines identified by the
KEGG_CHEMOKINE_SIGNALING_PATHWAY

and

BIOCARTA_CYTOKINE_PATHWAY were identified in the dataset and used for
differential expression where indicated. Cluster 3.0 was used to median-center the
genes prior to heat map generation in Java TreeView.
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PROTEIN ANALYSIS
Protein isolation
The total protein was isolated by lysing cells with RIPA buffer, and the
protein concentrations were determined using BCA kit (Pierce™ BCA Protein
Assay Kit (Thermo Scientific, Rockford, IL, USA).
Western blot analysis
Protein samples (40 μg or 25 μg) were electrophoresed on 10% sodium
dodecyl sulfate (SDS) polyacrylamide gels and transferred onto Immobilon-p
Transfer membrane (Millipore, Billerica, Massachusetts, USA). Membranes were
blocked with 3% BSA in PBS for 1 hour at room temperature. Membranes were
probed with respective specific primary antibodies (according to dilutions in Table
2.1) overnight at 4˚C. Membranes were washed with tween 20 tris-buffered saline
(TTBS) buffer, three times and probed with respective secondary antibodies.
Following washing with TTBS buffer membranes were visualized using Luminata
Forte Western HRP Substrate Kit (Millipore, Billerica, MA).
Enzyme-linked immunosorbent assay (ELISA)
Murine CXCL1,2,5 and 7
Murine cells were seeded at 1x105 density in a six-well plate then treated
with respective treatment for the respective time points. The supernatants of
cultured cells were collected for ELISA. ELISA assays for mCXCL1, mCXCL2,
mCXCL5, and mCXCL7 were performed using a duoset kit (R & D Systems,
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Minneapolis, MN, USA) according to the manufacturer’s protocol using Bio-Tek
plate reader (Winooski, VT). Briefly, plate preparation was done by diluting the
capture antibody to the working concentration with PBS and using it to coat the 96well microplate with 100 μl per well that was then incubated overnight at room
temperature. Next day, the coated microplate was washed three times with wash
buffer (~400 µl) per well then dried by aspirating the liquid and blotting inverted
against paper towels. Plates were then blocked by adding 300 μl of the reagent
diluent to each well followed by 1h incubation. After another course of three-time
washing, 100 µl of each sample or standard (diluted with sample diluent) was
added to the respective well and incubated for 2h at room temperature. Wells were
then washed three times with PBS and a 100 µl of the detection antibody working
dilution was added per well for 2h followed by three-time washing and adding of
the Streptavidin-HRP (100 µl) per well for 20 min in the dark. Lastly, the wells were
washed three times then 100 μl of the substrate was added to each well for 20 min
in the dark and reaction was stopped by adding 50 μl of the stop solution to each
well. Optical density was determined at 450 nm wavelength.
Human CXCL8 and FGF-2
Human cells were seeded according to their respective experiment and
supernatants were taken for ELISA analysis.
CXCL8 levels in culture supernatants were determined using an ELISA kit
paired antibody purchased from Pierce Inc. (Woburn, MA), according to
manufacturer instructions. Briefly, 100 µl of the primary monoclonal antibody
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against CXCL8 (2 µg/ml) was coated in Immulon plates in each well. After 1h of
incubation at 37oC, the plates were washed and blocked for 1h with blocking buffer
(4 % BSA in PBS). After washing the plates four times, 50 µl culture supernatants
or standards at different concentrations (recombinant CXCL8 protein, Endogen
Inc. Woburn, MA) and 50 µl of biotinylated CXCL8 Ab was added to each well.
After 2h of incubation, the plates were washed, and the immunoreactivity
determined using the avidin-HRP-TMB detection system (Dako Labs. Denmark).
The reactions were stopped by addition of 50 µl of 0.18 N H2SO4 and absorbance
determined using an ELISA microtiter plate reader (Bio-Tek Instruments Inc.
Winooski, VT) at 450 nm. A curve of the absorbance versus the concentration of
CXCL8 in the standard wells was plotted. By comparing the absorbance of the
samples to the standard curve, we determined the concentration of CXCL8 in the
unknown samples.
For analyzing levels of FGF-2, we used direct ELISA. Samples and different
concentrations of recombinant FGF-2 protein (for standard curve) was coated onto
ELISA plate overnight. Following washing and blocking non-specific activity, 100
µl of anti-FGF-2 antibody (R & D System, Minneapolis MN) was added into each
well. Following two hours of incubation, samples were incubated with biotinylated
secondary antibody and immunoreactivity was determined using avidin-HRP-TMB
detection system. A curve of the absorbance versus the concentration of FGF-2 in
the standard wells was plotted. By comparing the absorbance of the samples to
the standard curve, we determined the concentration of FGF-2 in the unknown
samples.
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Immunofluorescence (IF)
Cells were cultured on four-well chamber slides and treated according to
their respective experiment. After ceasing the treatment, cells were washed three
times with PBS and fixed using 4% paraformaldehyde, then again washed with
PBS for three times.

Cells were then blocked with antibody diluent (BD

Biosciences) or blocking buffer (PBS with 3% BSA and 0.1% Saponin) for
cytoplasmic targets. Cells were probed with the respective antibody (according to
Table 2.1) at 4˚C overnight. The next day, slides were stained with the respective
antibody and counterstained with the nucleic staining 4, 6 diamidino-2phenylindole (DAPI). Finally, slides were mounted with Vectashield® mounting
medium (Vector Laboratories, Burlingame, CA, USA) and observed under a
fluorescent microscope.
Immunohistochemistry (IHC)
Sections of 4μm thick from formalin-fixed, paraffin-embedded tissues were
deparaffinized with xylene and rehydrated by incubating with decreasing ethanol
concentrations. Antigen retrieval was performed using sodium citrate buffer (pH =
6.0) and microwaving for 10 minutes. Endogenous peroxidase was blocked by
incubating with 3% hydrogen peroxide in methanol for 30 minutes. After blocking
non-specific binding by incubating with serum, slides were probed with primary
antibody (Table 2.1) overnight at 4ºC. Slides were washed, and the appropriate
secondary antibodies were added. Immunoreactivity was detected using the ABC
Elite Kit and 3, 3 diaminobenzidine substrate kit (DAB) from (Vector Laboratories,
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Burlingame, CA) according to the manufacturer standard protocols. A reddish
brown precipitate indicated positive staining. Nuclei were counterstained with
hematoxylin. Quantitation was done by counting positive cells in five independent
areas at x400.
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IN VITRO CELL-BASED ASSAYS
In vitro cell proliferation assay: 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT)
Cells were seeded at appropriate densities in 96-well plates and were
allowed to adhere overnight. Cells were washed with HBSS and were incubated
with serum-free media alone or with other treatments (conditioned media, CXCR2
inhibitors, exogenous CXCR2 ligands) for 72 hours. Cell viability was determined
by MTT assay as previously described (Li et al., 2001). Briefly, 50 µl of the MTT
reagent (Thermo Fisher Scientific, Fair Lawn, NJ) was added to each well and
incubated for 2-4h. Media and MTT were removed and replaced by 100 µl of
dimethyl sulfoxide (DMSO; Thermo Fisher Scientific, Fair Lawn, NJ)
The formula calculated percent inhibition of cell growth: [100 - (A/B) x 100],
where ‘A’ and ‘B’ are the absorbance of the treated and Control group, respectively.
Percentage of cell growth was calculated by the formula: [(A/B) x 100], where ‘A’
and ‘B’ are the absorbance of treatment and control group respectively.
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STATISTICAL ANALYSIS
The statistical analysis was performed using Prism 7 (GraphPad) software.
Statistical method and sample size (n; the number of replicates) are indicated in
the figure legends. Statistical significance was defined as p<0.05. Error bars on
figures show standard error of the mean (SEM). Two-tailed Student's t-test,
ANOVA and Posthoc comparisons using Mann-Whitney tests with a Bonferroni
adjustment were performed when appropriate as indicated in figure legends.
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Figure 2.1: Mouse models
Syngeneic mouse models: C57BL/6 mice (wildtype or Cxcr2-/-) orthotopically
transplanted with PDAC murine cells KC (oncogenic Kras) or Panc02 (wildtype
Kras).
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Table 2. 1: List of antibodies
Species
reactivity in
this paper
Mouse/Human
Mouse/Human
Mouse/Human
Mouse/Human
Mouse/Human
Mouse/Human

Antibody

Supplier

Catalogue
number

CXCR2
αSMA
FAP
CD10
p50
HSP70

Gift from Dr. Strieter
ThermoFisher
Abcam
Abcam
Biolegend
Santacruz
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MA5-11547
ab207178
ab951
616701
sc-32239

Host
species
Goat
Mouse
Rabbit
Mouse
Mouse

Dilution
IHC/IF
(WB)
1:1000
1:250 (1:500)
1:1000
1:50
1:100
(1:250)

Table 2. 2: List of primers
Gene
Cxcl1

Temp. (oC)
55˚

Species
Murine

Cxcl2

57˚

Murine

Cxcl3

68˚

Murine

Cxcl5

68˚

Murine

Cxcl7

57˚

Murine

Ccl5

56˚

Murine

Ccl3

56˚

Murine

Ccl2

56˚

Murine

IL1

56˚

Murine

IL4

56˚

Murine

IL6

55˚

Murine

IL10

57˚

Murine

IL12

57˚

Murine

IL13

55˚

Murine

IL17

55˚

Murine

IFN-γ

57˚

Murine

TNF-α

57˚

Murine

Rpl13a

58˚

Murine

Actin β

57˚

Murine

PPIA

57˚

Murine

HPRT

57˚

Murine

Acta2 (αSMA)

56˚

Murine

COL1A1 (Collagen I)

56˚

Murine

COL4A1 (Collagen IV)

55˚

Murine

Sequence
Forward 5’-TCGCTTCTCTGTGCAGCGCT-3’
Reverse 5’- GTGGTTGACACTTAGTGGTCT C-3’
Forward 5’-AGTGAACTGCGCTGTCAATG-3’
Reverse 5’-TTCAGGGTCAAGGCAAACTT-3’
Forward 5’-GCAAGTCCAGCTGAGCCGGGA-3’
Reverse 5’-GACACCGTTGGGATGGATCGCTTT-3’
Forward 5’-ATGGCGCCGCTGGCATTTCT-3’
Reverse 5’-CGCAGCTCCGTTGCGGCTAT-3’
Forward 5’-CTCAGACCTTACATCGTCCTGC-3’
Reverse 5’-AGCGCAACAAGGATCGTCCTGC-3’
Forward 5’-GCTGCTTTGCCTACCTCTCC-3’
Reverse 5’-TCGAGTGACAAACACGACTGC-3’
Forward 5’-TTCTCTGTACCATGACACTCTGC-3’
Reverse 5’-CGTGGAATCTTCCGGCTGTAG-3’
Forward 5’-TTAAAAACCTGGATCGGAACCAA-3’
Reverse 5’-GCATTAGCTTCAGATTTACGGGT-3’
Forward 5’-GCAACTGTTCCTGAACTCAACT-3’
Reverse 5’-ATCTTTTGGGGTCCGTCAACT-3’
Forward 5’-GGTCTCAACCCCCAGCTAGT-3’
Reverse 5’-GCCGATGATCTCTCTCAAGTGAT-3’
Forward 5’-CCTCTGGTCTTCTGGAGTACC-3’
Reverse 5’-ACTCCTTCTGTGACTCCAGC-3’
Forward 5’-GCTCTTACTGACTGGCATGAG-3’
Reverse 5’-CGCAGCTCTAGGAGCATGTG-3’
Forward 5’-TGGGTTTGCCATCGTTTTGCTG-3’
Reverse 5’-ACAGGTGAGGTTCACTGTTTCT-3’
Forward 5’-CCTGGCTCTTGCTTGCCTT-3’
Reverse 5’-GGTCTTGTGTGATGTTGCTCA-3’
Forward 5’-TTTAACTCCCTTGGCGCAAAA-3’
Reverse 5’-CTTTCCCTCCGCATTGACAC-3’
Forward 5’-ATGAACGCTACACACTGCATC-3’
Reverse 5’-CCATCCTTTTGCCAGTTCCTC-3’
Forward 5’-CCCTCACACTCAGATCATCTTCT-3’
Reverse 5’-GCTACGACGTGGGCTACAG-3’
Forward 5’-ACTCTGGAGGAGAAACGGAAGG-3’
Reverse 5’-CAGGCATGAGGCAAACAGTC-3’
Forward 5’-GGCTGTATTCCCCTCCATCG-3’
Reverse 5’-CCAGTTGGTAACAATGCCATGT-3’
Forward 5’-TGTGCCAGGGTGGTGACTTT-3’
Reverse 5’-CGTTTGTGTTTGGTCCAGCAT-3’
Forward 5’-CCTAAGATGAGCGCAAGTTGAA -3’
Reverse 5’-CCACAGGACTAGAACACCTGCTAA-3’
Forward 5’-CCCAGACATCAGGGAGTAATGG-3’
Reverse 5’-TCTATCGGATACTTCAGCGTCA-3’
Forward 5’-GCCCGAACCCCAAGGAAAAGAAGC-3’
Reverse 5’-CTGGGAGGCCTCGGTGGACATTAG-3’
Forward 5’-TCCGGGAGAGATTGGTTTCC-3’
Reverse 5’-CTGGCCTATAAGCCCTGGT-3’
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CHAPTER III: CAFS ENHANCE SURVIVAL AND PROGRESSION OF THE
AGGRESSIVE PANCREATIC TUMOR VIA FGF-2 AND CXCL8

This chapter in part is derived from:
Awaji M, Futakuchi, M, Heavican T, Iqbal J, and Singh RK. Cancer-associated
fibroblasts enhance survival and progression of the aggressive pancreatic tumor
via FGF-2 and CXCL8. Cancer Microenvironment., 2019 (In press).
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ABSTRACT
PDAC remains one of the most challenging human cancers. Desmoplasia
is predominant in this disease exhibiting a strong stromal reaction with an
abundance of the CAFs. We aimed in this study to investigate the reciprocal
interaction between the tumor cells and the CAFs and its effect on tumor cells
survival. We hypothesized that the survival of pancreatic cancer cell with
aggressive phenotype is modulated by the interactions between malignant
pancreatic tumor cells and surrounding CAFs. To examine this, we utilized coculture methods where tumor cells with different malignant potentials, HPAF (low)
HPAF-CD11 (moderate/high) co-cultured with CAFs. CAFs-conditioned media
increased the growth of HPAF-CD11 but not HPAF cells and increased CXCL8
levels highly in HPAF-CD11 and slightly in HPAF. The growth stimulatory effect
and elevated CXCL8 level caused by CAFs-conditioned media were diminished by
neutralizing the fibroblast growth factor-2 (FGF-2). Also, conditioned media of
HPAF-CD11 increased CAFs cell number whereas that of HPAF did not, and these
effects were suppressed by neutralizing CXCL8. Furthermore, data from gene
expression microarray study exhibited different expression profiles between HPAF
and HPAF-CD11 when co-culture with CAFs. A significant increase in CXCL8 and
FGF-2 expression was observed with HPAF-CD11/CAFs co-culture and to a lower
extent with HPAF/CAFs co-culture. Together, these data demonstrate a paracrine
bi-directional interaction between pancreatic tumor cells and the CAFs through
CXCL8 and FGF-2 that helps the tumor growth. Future in-depth study of these
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pathways will assist in obtaining diagnostic and therapeutic tools for pancreatic
ductal adenocarcinoma.
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INTRODUCTION
PDAC is the most common type of pancreatic cancers, the fourth leading
cause of cancer deaths in the United States (Siegel, Miller et al. 2018). The
increased incidence of the disease, as well as the cellular and molecular
complexity of the tumor, makes it very challenging to manage. A chance of cure
exists for only a minority of the patients, those with locally limited and surgically
resectable tumors (Warshaw and Fernandez-del Castillo 1992). At the time of
diagnosis, the majority of PDAC patients present at advanced stages beyond
surgical resection. Studying the complex cellular and molecular interaction
between malignant cells and other cells in the tumor microenvironment can shed
more light on how the diseases initiate progresses and spreads.
Desmoplasia is of particular predominance in PDAC exhibiting a strong
stromal reaction (Kuniyasu, Abbruzzese et al. 2001, Iacobuzio-Donahue, Ryu et
al. 2002, Watanabe, Hasebe et al. 2003). A consistently low ratio of the infiltrating
adenocarcinoma component relative to this abundant desmoplastic response is
unique to PDAC, in contrast to infiltrating carcinomas in other organ or tissue types
(Seymour, Hruban et al. 1994, Kalluri 2016). Typically, these invasive pancreatic
tumors are composed of infiltrating adenocarcinoma surrounded by a
predominance of dense fibrous (or desmoplastic) stroma (Kloppel, Lingenthal et
al. 1985), which itself contains proliferating CAFs, small endothelial-lined vessels,
inflammatory cells, and trapped residual atrophic parenchymal components of the
organ invaded (Ryu, Jones et al. 2001). CAFs, represent the fibrotic component of
the tumor microenvironment, are derived from cells of multiple origins including
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tissue resident fibroblasts, bone marrow-derived mesenchymal cells, fibrocytes,
and PSCs (Öhlund, Elyada et al. 2014). PSCs, in particular, have gained much
attention more than other subsets of CAFs. PSCs, similar to other stellate cells
found in other organs such as in liver, kidneys, and lungs, are known to modulate
physiological functions by storing vitamin-A at their quiescent state and tissue
maintenance and repair at the activated state (Omary, Lugea et al. 2007, Apte,
Wilson et al. 2013, Apte, Pirola et al. 2015, Moir, Mann et al. 2015). In PDAC,
activated PSCs have been described to be involved in tumorigenesis, therapy
resistance, and metastasis (Xu, Vonlaufen et al. 2010, Lonardo, Frias-Aldeguer et
al. 2012, McCarroll, Naim et al. 2014, Moir, Mann et al. 2015, Zambirinis, Levie et
al. 2015). Interactions between the malignant cells and surrounding stromal CAFs
have been suggested to play a critical role in tumor invasion and progression
(Grey, Schor et al. 1989, Camps, Chang et al. 1990). Once tumor cells have spread
to different microenvironment, their subsequent growth will depend on the
compatibility of the “seed” with the “soil” that they encounter in the
microenvironment (Paget 1889, Hart 1982), which depend on the molecular
interactions between cancer cells and the stromal cells in the different
microenvironment (Chambers, Groom et al. 2002, Fidler, Yano et al. 2002).
Invasive cancers do not exist in isolation; rather, they arise from and intimately
interact with non-neoplastic host cells (Maehara, Matsumoto et al. 2001, Qian,
Mizumoto et al. 2003).
For long, CAFs have been regarded for their role in the formation of
desmoplasia, by producing excessive amounts of ECM proteins (Apte and Wilson
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2004). Desmoplasia aids in acquiring resistance to current chemotherapy
treatments (Olive, Jacobetz et al. 2009, Jacobetz, Chan et al. 2012, Provenzano,
Cuevas et al. 2012). Nonetheless, recent literature describes a vast network of
CAFs interactions beyond the desmoplasia formation. Through their network of
secreted factors, such as cytokine, chemokines and growth factors, CAFs can
interact with the multiple components in the tumor microenvironment to modulate
tumor progression in different malignancies (De Wever and Mareel 2003, Micke
and tman 2004, Cheng, Bhowmick et al. 2005, Paulsson and Micke 2014).
FGF-2 is a member of the FGF family that control multiple cellular
processes including proliferation, differentiation, survival, and motility (Basilico and
Moscatelli 1992). In the context of cancer, FGF-2 has been shown to promote
tumor progression (Polnaszek, Kwabi-Addo et al. 2003). Enhanced FGF-2 protein
levels have been shown to correlate with shorter postoperative survival of patients
with PDAC (Kleeff, Kothari et al. 2004). Furthermore, FGF-2 was linked to PDAC
invasion via its activity in PSCs (Coleman, Chioni et al. 2014).
A member of the CXC chemokine family, CXCL8 signals through CXCR1
and CXCR2 chemokine receptors. These chemokines are known for their role in
inflammation by recruiting inflammatory cells and inducing angiogenesis. In
malignant

tumors,

sustained

CXCL8

signaling

is

associated

with

immunosuppression, angiogenesis, and tumor growth; thus, essential to the
progression of PDAC (Saintigny, Massarelli et al. 2012, Liu, Li et al. 2016, Purohit,
Varney et al. 2016). There is evidence that CXCL8 and FGF-2 are involved in
tumor-stromal interaction (Giri and Ittmann 2001, Coleman, Chioni et al. 2014).
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We hypothesized that the aggressive phenotype of PDAC depends on their
interaction with CAFs, which involves FGF-2 and CXCL8. To test this hypothesis,
we examined the effect of CAFs on pancreatic tumor cells with different malignant
potential, HPAF (low) and HPAF-CD11 (moderate/high). HPAF-CD11 is derived
from the parent cell line HPAF, where both cells show well-differentiation features
and mutations in both Kras and TP53 (Kim, Kern et al. 1989, Egami, Takiyama et
al. 1990, Batra, Metzgar et al. 1991, Wang, Knezetic et al. 1996, Ding, Fehsenfeld
et al. 2000). We demonstrated that the aggressive phenotype of PDAC has a
stronger bi-directional interaction with CAFs through paracrine factors such as
FGF-2 and CXCL8.
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RESULTS
Aggressive pancreatic tumor cell survived following co-culture with
fibroblasts in the absence of serum
We examined the growth of HPAF and HPAF-CD11 cells in the presence
or absence of serum-containing media when cultured with or without fibroblasts.
Both HPAF and HPAF-CD11 cells showed serum dependency irrespective of their
aggressive differential phenotype when cultured in the absence of fibroblasts
(Figure 3.1A and 3.1B). Further, the growth of HPAF cells was inhibited following
co-culture with fibroblasts (BJ cells monolayer) in the presence of or absence of
serum (Figure 3.1C) as compared to HPAF cells cultured alone. The level of
inhibition of HPAF cells growth following co-culture with fibroblasts was similar to
that observed when HPAF cells alone were cultured in the absence of serum
(Figure 3.1A). In contrast, we observed an increased survival and growth of
HPAF-CD11 cells following co-culture with fibroblasts (BJ cells monolayer).
Interestingly the growth of HPAF-CD11 cells was enhanced in following co-culture
with fibroblasts in the absence of serum (Figure 3.1D).
Survival of tumor cells is mediated by CAFs conditioned media
To evaluate whether the survival of HPAF-CD11 cells on the
fibroblasts monolayer was mediated by the direct contact or paracrine factors,
HPAF and HPAF-CD11 cells were incubated with CAF-conditioned media or ECM
generated from CAFs, and the increase in cell number was quantitated. No
increase in the cell number was observed in HPAF cells in response to CAFs
conditioned media, and further inhibition was detected with ECM culture (Figure
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3.2A). We observed a significant increase in the number of HPAF-CD11 cells
following co-culture with both CAFs conditioned media and CAFs ECM (Figure
2B). The increase in HPAF-CD11 cells cultured with CAFs conditioned media was
greater than that observed in response to ECM but less than that observed with
serum containing media (Figure 3.2B). Next, we examined the dose-dependence
of CAFs-conditioned media on the growth of HPAF-CD11 cell (Figure 3.2C) and
demonstrated that increasing concentrations of CAFs conditioned media
increased the growth of HPAF-CD11 cells. Together, we perceive that CAFsderived paracrine factors contribute to the survival of the aggressive PDAC cells.
CAFs promote tumor cell survival via FGF-2
To determine the putative growth factors present in CAFs conditioned media, we
examined the effect of the neutralizing antibodies of FGF-2 and CXCL8, which have been
shown to be involved in the tumor-stromal interaction (Giri and Ittmann 2001, Coleman,
Chioni et al. 2014), on the survival of HPAF-CD11 cells. Anti-FGF-2 antibody treatment
significantly abrogated the increase of cell number of HPAF-CD11 following culture with
CAFs conditioned media (Figure 3.3A), while anti-CXCL8 antibody treatment did not
(Figure 3.3B). To confirm that FGF-2 is produced by CAFs, we performed ELISA on the
CAF supernatant collected in serum-free media or complete media (Figure 3.3C). These
results indicate that FGF-2 but not CXCL8 in the CAFs conditioned media was involved in
the survival of HPAF-CD11.

FGF-2 secreted by CAF induces CXCL8 production in tumor cells
CXCL8 and other CXC chemokines that signal through CXCR1/2 axis are
known to be expressed in PDAC cells (Le, Shi et al. 2000, Takamori, Oades et al.
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2000, Frick, Rubie et al. 2008). Autocrine and paracrine signaling through
CXCR1/2 axis plays a vital role in the progression of PDAC by promoting tumor
cells growth, angiogenesis, immunosuppression and chemotherapy resistance
(Strieter, Burdick et al. 2006, Highfill, Cui et al. 2014, Chan, Hsu et al. 2016,
Purohit, Varney et al. 2016). To examine the involvement of FGF-2 in the CXCL8
production by PDAC cells, we determined CXCL8 production in HPAF and HPAFCD11 cell after treatment with CAFs-conditioned media using ELISA. Our data
shows that HPAF-CD11 produce more CXCL8 than their HPAF counterparts by
comparing CXCL8 levels produced in serum-free media treatment as well as in
response to CAFs-conditioned media treatment (Figure 3.4A-B). By comparing
the CXCL8 production in each cell in response to CAFs-conditioned media, we
show that CAFs-conditioned media increased CXCL8 level in both HPAF and
HPAF-CD11 cells, and neutralizing FGF-2 has lowered the CXCL8 inducing effect
of the CAFs-conditioned media (Figure 3.4C and 3.4D).
Effect of tumor cell conditioned media on the survival of CAFs
Next, we examined the effect of the conditioned media from PDAC cells with
different aggressiveness on the survival of CAFs. CAFs were incubated with the
conditioned media of HPAF or and HPAF-CD11 for 1, 2, and 3 days, and the
increase in cell number was quantitated. We observed a significant increase in the
number of CAFs following co-culture with conditioned media of HPAF-CD11 cell at
each time point but not with that of HPAF (Figure 3.5A). To determine the putative
growth factors present in the conditioned media of HPAF-CD11, we examined the
effect of the neutralizing antibodies of CXCL8 (Figure 3.5B). Anti-CXCL8 antibody
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treatment significantly abrogated the increase of cell number of CAFs following
culture with HPAF-CD11 conditioned media. These results indicate that CXCL8
was involved in the survival of CAFs by the conditioned media of PDAC cells.
Aggressiveness-dependent gene expression of tumor cells when cocultured with CAFs
Finally, we used gene expression microarray to explore the expressional
differences between HPAF and HPAF-CD11 cells upon their co-cultured with CAF.
Distinct gene expression profiles were observed for HPAF and HPAF-CD11 when
compared alone or in co-culture. More focused look into the expression profile of
paracrine factors revealed that CAFs are the major contributor of many cytokines
and chemokines (Figure 3.6A). Comparing HPAF/CAF co-culture to HPAFCD11/CAF co-culture revealed upregulation of motility supporting gene ELMO1 in
HPAF-CD11 co-culture, whereas, mainly cytokines and chemokines were
upregulated in the HPAF co-culture (Figure 3.6A). Targeted look into CXCL8 and
FGF-2 expression exhibited that CAFs are the leading producer of CXCL8 and that
CXCL8 was upregulated in the co-culture condition compared to tumor cells
cultured alone for both HPAF and HPAF-CD11 (Figure 3.6B). For FGF-2, only
HPAF-CD11 co-culture exhibited significance upregulation of the gene compared
to the tumor cells cultured alone (Figure 3.6B). Together, these data demonstrate
the versatility of CAFs and their ability to support tumor cells in an aggressivedependent manner.
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DISCUSSION
PDAC, one of the most malignant tumors, is often characterized by an
abundant desmoplastic stroma. CAFs, which constitute a primary stromal
compartment in PDAC, have been shown to promote the invasive growth of
several cancer types such as breast, prostate, and lung (Tuxhorn, Ayala et al.
2002, Micke and tman 2004). CAFs are often only associated with excess
extracellular matrix production; thus, their contribution to desmoplasia (Apte and
Wilson 2004). Recent studies have addressed the role of CAFs in pancreatic tumor
aggressiveness. Non-irradiated CAFs significantly increased the invasive ability of
pancreatic cancer cells and the invasiveness was further accelerated when they
were co-cultured with irradiated CAFs (Ohuchida, Mizumoto et al. 2004). Nitric
Oxide released by CAFs has been shown to lead to the upregulation of IL-1β in
pancreatic carcinoma cells, leading to the induction of chemotherapy resistance in
these tumor cells (Muerkoster, Wegehenkel et al. 2004). CAFs can produce many
paracrine factors including chemokines, cytokines and growth factor, which allow
interaction

and

subsequent

modulation

of

other

cells

in

the

tumor

microenvironment (Öhlund, Elyada et al. 2014). This secretory role of CAFs
remained under-investigated. In the present study, we demonstrated that
pancreatic tumors with more aggressive phenotype could interact with CAFs more
than non-aggressive cells. These data underscored the importance of the
interaction with CAFs in the exertion of the malignant potential of the pancreatic
tumor.
FGF-2 is expressed in pancreas cancer (Yamanaka, Friess et al. 1993), as well
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as in many other malignant neoplasms (Feng, Wang et al. 1997, Relf, LeJeune et
al. 1997). FGFs bind to a family of transmembrane tyrosine kinase receptors
(FGFRs 1-4), and FGFR-1 and FGFR-4 are potent receptors for FGF-2 (Ornitz, Xu
et al. 1996). A member of the CXC chemokine family, CXCL8, its production has
been

correlated

with

tumor

growth,

immunosuppression,

resistance

to

chemotherapy, angiogenesis, and increased metastatic potential of PDAC
(Saintigny, Massarelli et al. 2012, Liu, Li et al. 2016).
In the current study, we demonstrate a bi-directional interaction between tumor
cells and CAFs that creates a feedforward loop to promote the survival of the tumor
cells in PDAC. The said interaction was more obvious with HPAF-CD11 cells that
acquire more PDAC aggressive features. Culturing tumor cells on top of CAFs
monolayer proved that the interaction between malignant cells and CAFs could
promote survival and growth of PDAC cells. Nonetheless, culturing tumor cells in
CAFs-derived conditioned media demonstrated that the survival stimulation effect
of CAFs on malignant cells is mediated through paracrine factors rather than direct
interaction. The use of neutralizing antibodies demonstrated that FGF-2 is the
putative factor that stimulates malignant cells survival; whereas, it is clear that
FGF-2 was present in CAFs-conditioned media, the difference in the expression of
the appropriate FGF-2 receptors is possibly responsible for the difference between
HPAF and HPAF-CD11.

Moreover, CXCL8 has been shown to enhance

endothelial cell proliferation and to regulate angiogenesis (Li, Dubey et al. 2003,
Waugh and Wilson 2008). In this study, we show that CAFs-conditioned media
increased CXCL8 production by HPAF-CD11. Subsequently, CXCL8 may induce
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angiogenesis necessary for further tumor progression. On the other hand, HPAF
cells that carry less aggressive potential produce less CXCL8. Therefore, the
CXCL8 level induced by CAFs-conditioned media may be one of the determinants
for malignant potential. Recently, CXCL8 has been shown to be produced by
prostatic epithelial cells of benign prostatic hyperplasia which consists of slow but
progressive growth of both epithelial and stromal cell and can act as a paracrine
inducer of FGF-2 production by prostatic stromal cells in vitro (Giri and Ittmann
2001). In our study, conditioned media of the more aggressive PDAC cells, HPAFCD11, stimulated and maintained the survival of CAFs through the secretion of
CXCL8. Therefore, pancreatic tumor cell-derived CXCL8, released as a
consequence of FGF-2 stimulation, may act on CAFs to stimulate further FGF-2
production. On the other hand, we have shown that CAFs derived FGF-2 can serve
as a paracrine inducer of CXCL8 production by pancreatic tumor cells.
Looking into the differential gene expression profiles of HPAF and HPAF-CD11
upon their co-culture with CAFs can reveal the extent of CAFs contribution to tumor
progression. CAFs appear to have a high baseline of several cytokines and
chemokines including CXCL8. An interesting observation is that HPAF-CD11
cell/CAFs co-culture upregulates ELMO1 gene that has been associated with
motility (Grimsley, Kinchen et al. 2003, Sanui 2003). If we put this together with the
ability of CXCL8 to induce angiogenesis, we can assume that CAFs can contribute
to tumor cells spread to other organs.
In conclusion, interactions between pancreatic tumor cells and CAFs promote
the survival of tumor cells with aggressive potentials and promote CXCL8
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production. CXCL8, released as a consequence of FGF-2 stimulation, act on CAFs
to stimulate further FGF-2 production. Thus, such bi-directional interactions
between pancreatic tumor cells and CAFs help the tumor growth in different
microenvironments, which leads to the pancreatic tumor progression and spread.
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Figure 3.1: Fibroblasts promote the survival of aggressive pancreatic tumor
cell
(A) Light microscope images of HPAF cells cultured in complete media or serumfree media. (B) Light microscope images of HPAF-CD11 cells cultured in complete
media or serum-free media. (C) Light microscope images of HPAF cells cultured
on top of fibroblasts (BJ) monolayer with complete media, or serum-free media.
(D) Light microscope images of HPAF-CD11 cells cultured on top of fibroblasts
(BJ) monolayer with complete media, or serum-free media.
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Figure 3.2: CAFs promotes the survival of tumor cells through paracrine
contact
(A and B) Survival of HPAF cells (A) and HPAF-CD11 (B) following their culture
with CAFs-ECM, CAFs-conditioned media, or complete media as compared to
serum-free media. (C) Survival of HPAF-CD11 cells in increasing amounts of
CAFs- conditioned media to serum-free media. (n=3), student’s t-test. *p<0.05,
**p<0.01, ***p<0.001
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Figure 3.3: Effects of CAFs conditioned media on the survival of HPAFCD11 is mediated by FGF-2
(A) Number increase of HPAF-CD11 in response to CAFs-conditioned media +/FGF-2 neutralizing antibody as compared to serum-free media. (B) Number
increase of HPAF-CD11 in response to CAFs-conditioned media +/- CXCL8
neutralizing antibody as compared to serum-free media.

(C) FGF-2

concentrations, evaluated by ELISA, in the supernatant of CAF incubated in
serum-free media or complete media.

(n=3), student’s t-test. *p<0.05, **p<0.01,

***p<0.001
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Figure 3.4: FGF-2 in the CAFs conditioned media promotes the CXCL8
production of pancreatic tumor cells
(A) CXCL8 concentration, evaluated by ELISA, in the supernatant of HPAF cells
and (B) HPAF-CD11 after treatment with serum-free media or CAFs-conditioned
media. (C) CXCL8 concentration, evaluated by ELISA, in the supernatant of HPAF
cells after treatment with CAFs-conditioned media +/- FGF-2 neutralizing. (D)
CXCL8 concentration, evaluated by ELISA, in the supernatant of HPAF-CD11 cells
after treatment with CAFs-conditioned media +/- FGF-2 neutralizing. (n=3),
student’s t-test. *p<0.05, **p<0.01, ***p<0.001
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Figure 3.5: Effect of tumor cell conditioned media on the survival of CAFs
(A) Survival, increase in cell number, of CAFs incubated with the conditioned
media of HPAF or and HPAF-CD11 for 1, 2, and 3 days, and the increase in cell
number was quantitated. (B) Net growth, determined by the increase in cell
number, of CAFs in HPAF-CD11 conditioned media +/- CXCL8 neutralizing
antibody. (n=3), student’s t-test. *p<0.05, **p<0.01, ***p<0.001
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Figure 3.6: Differential gene expression of tumor cells cultured with CAFs
(A) Heat map of gene expression of HPAF and HPAF-CD11 cultured alone or with
CAFs determined using gene expression microarray. Heat maps show chemokines
and cytokine with > 2-fold increase. (B) Expression of CXCL8, represented as
normalized signal intensity, in HPAF and HPAF-CD11 cultured alone or with CAFs
determined using gene expression microarray.

(C)

Expression of FGF-2,

represented as normalized signal intensity, in HPAF and HPAF-CD11 cultured
alone or with CAFs determined using gene expression microarray.
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CHAPTER IV: CXCR2 SIGNALING ACTIVATES NF-KB AND PROMOTES
SECRETORY CAFS
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ABSTRACT
Due to its late detection and low success of current therapies, PDAC
remains one of the most challenging malignancies. Desmoplasia and tumorsupporting inflammation are hallmarks of PDAC. In addition to the autonomous
aggressiveness feature of PC malignant cells, host tumor microenvironment
contribute greatly to tumor progression and spread. CAFs, a major component of
the tumor microenvironment in PDAC, are implicated in facilitating therapy
resistance and metastasis. Recent reports emphasized the concurrence of
multiple subtypes of CAFs that carry out different roles. CXCR2 is a chemokine
receptor that is known for its role during inflammation and its adverse role in PDAC.
Oncogenic Kras upregulates CXCR2 and its ligands and; thus, contribute to tumor
proliferation, immunosuppression, therapy resistance by stemness induction. The
deletion of CXCR2 in a PDAC syngeneic mouse model, render fibrosis revealing
a potential undescribed role of CXCR2 in regulating CAFs. We hypothesize that
CXCR2 regulates CAFs function in PDAC and contribute to CAFs heterogeneity.
Using co-culture methods, gene and protein expression methods, we
demonstrated that PDAC tumor cells with oncogenic Kras express more CXCR2
ligands. CXCR2 ligands derived from PDAC cells inhibited CAFs growth,
decreased the expression of the myofibroblasts-associated markers including
αSMA and collagen I, and increased the expression of immunosuppressive
cytokines and tumor-promoting chemokines including IL-4, IL-10, IL-13 and
CXCL7 through the activation of NFκB. Together, we demonstrate that sustained
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signaling through CXCR2 activates NFκB and induces a secretory phenotype of
CAFs in PDAC that upregulates pro-tumor factors.

97

INTRODUCTION
Pancreatic cancer, one of deadliest human cancers, is the fourth leading
cause of cancer-related deaths in the USA (Siegel, Miller et al. 2018). The lack of
both early detection tools and viable treatment options made pancreatic cancer a
very stubborn and one of the deadliest human malignancies (Warshaw and
Fernandez-del Castillo 1992, Hidalgo 2010). Making progress in dealing with the
disease starts by understanding the complex cellular and molecular interactions
and identifying the checkpoints that are crucial for the disease initiation,
progression and spread. PDAC is the most common and most aggressive subtype
of pancreatic cancers (Fesinmeyer 2005, Bosman, Carneiro et al. 2010). PDAC
develops progressively as a result of accumulating genetic and epigenetic
alterations (Hruban and Fukushima 2007, Hruban and Adsay 2009). Oncogenic
Kras often develops very early before the inception of the full-blown disease.
Premalignant lesions, known as PanIN, develop with the Kras mutation and not
until other mutations such as the p53 and the Smad4 inactivation, the disease
transforms into a blunt PDAC (Hruban and Fukushima 2007). Oncogenic Kras is
tightly linked to inflammatory signals that contribute to tumor growth and
immunosuppression; thus, enabling disease progression (Grivennikov, Greten et
al. 2010, Baumgart, Chen et al. 2014, Hamada, Masamune et al. 2014). The
disease is additionally characterized by a dense and complex desmoplastic tumor
microenvironment composed of ECM deposition, fibrotic cells, endothelial cells,
and immune cells (Chu, Kimmelman et al. 2007, Kleeff, Beckhove et al. 2007).
Inflammatory signals such as cytokines and chemokines secreted by the malignant
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cells and other components of the tumor microenvironment contribute to the
tumorigenicity and progression of PDAC (Grivennikov, Greten et al. 2010,
Baumgart, Chen et al. 2014, Hamada, Masamune et al. 2014). One of the major
inflammatory signals in PDAC is CXCR2 that has strong ties to the prominent
oncogenic Kras (Baumgart, Chen et al. 2014, Purohit, Varney et al. 2016).
CAFs represent a major component of PDAC tumor microenvironment
(Chu, Kimmelman et al. 2007, Kleeff, Beckhove et al. 2007). CAFs are fibrotic cells
of multiple origins including PSCs, resident fibroblasts, bone marrow-derived
mesenchymal stem cells, fibrocytes and others (Öhlund, Elyada et al. 2014). In
response to external cues, quiescent fibrotic cells get activated and when this
activation occurs in the context of cancer, they become CAFs (Omary, Lugea et
al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015). CAFs have been
associated with supporting tumor in all the stages from initiation to spread (Omary,
Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015). Myofibroblasts,
activated fibrotic cells with extensive ECM synthesis, have long been used as a
synonym for CAFs in the context of cancer (Omary, Lugea et al. 2007, Apte, Wilson
et al. 2013, Moir, Mann et al. 2015). More recent reports indicate the coexistence
of multiple functional subsets of CAFs (Ohlund, Handly-Santana et al. 2017, Su,
Chen et al. 2018). The typical myofibroblasts are characterized by upregulation of
αSMA and ECM molecules such as collagen I (Omary, Lugea et al. 2007, Apte,
Wilson et al. 2013, Moir, Mann et al. 2015). The other subset referred to as
inflammatory or secretory CAFs develops through paracrine signaling and tend to
have low expression of αSMA and high expression of inflammatory mediators
99

(Ohlund, Handly-Santana et al. 2017). This functional heterogeneity could explain
the versatility of CAFs and the failure of targeting desmoplasia to resolve PDAC
(Özdemir, Pentcheva-Hoang et al. 2014, Rhim, Oberstein et al. 2014).
Chemokines are small secreted molecules that are renowned for their role
in inflammation (Ransohoff 2009, Griffith, Sokol et al. 2014, Roy, Evans et al. 2014,
Hughes and Nibbs 2018). Based on the position of the conserved N-terminal
cysteine residues, they are classified into four families: C, CC, CXC, and CX3C.
Chemokine receptors are G-protein coupled receptor molecules (Ransohoff 2009,
Griffith, Sokol et al. 2014, Roy, Evans et al. 2014, Hughes and Nibbs 2018).
CXCR2 is the receptor for multiple chemokines that include a group of angiogenic
chemokines referred to as ELR+ CXC chemokines that include CXCL1-3, 5-7, and
8 that also interacts with CXCR1 (Bizzarri, Beccari et al. 2006, Strieter, Burdick et
al. 2006). CXCR2 signaling helps in recruiting granulocytes to the site of
inflammation and also enable angiogenesis (Bizzarri, Beccari et al. 2006, Strieter,
Burdick et al. 2006, Bajrami, Zhu et al. 2016, Zhang, Guo et al. 2018). These
features in the context of cancer can be considered adverse. The chemoattracting
ability of CXCR2 signaling allows recruitment of immunosuppressive cells such as
neutrophils and MDSCs (Highfill, Cui et al. 2014, Kumar, Donthireddy et al. 2017),
and the angiogenic feature of CXCR2 enables easy access for tumor growth and
spread (Waugh and Wilson 2008, Matsuo, Raimondo et al. 2009, Singh, Varney
et al. 2009). Furthermore, CXCR2 signaling can directly contribute to tumor growth
by promoting malignant cells proliferation (Waugh and Wilson 2008, Purohit,
Varney et al. 2016). Our group has demonstrated the presence of an association
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between the occurrence of oncogenic Kras and the progressive upregulation of
CXCR2 axis in PDAC (Purohit 2015, Purohit, Varney et al. 2016). In-vitro inhibition
of CXCR2 was able to reduce tumor cells proliferation, migration, and anchorage
(Purohit 2015, Purohit, Varney et al. 2016). Several attempts to assess if CXCR2
inhibition can be utilized as a target for PDAC treatment. Inhibiting CXCR2
disrupted tumor to stromal interaction and improved the survival in Kras+Tgfbr2KO
PDAC mouse model (Ijichi, Chytil et al. 2011).
Trp53R172H/+;

In KPC (LSL-KrasG12D/+; LSL-

Pdx1-Cre) mice, the global CXCR2 inhibition suppressed metastasis,

but the loss of CXCR2 in epithelial cells only was not able to inhibit metastasis
(Steele, Karim et al. 2016). Our group generated a syngeneic mouse model with a
global CXCR2 knockout (Cxcr2-/-) transplanted with cells from Pdx1-Cre; KrasG12D
(KC) mouse. In this model, CXCR2 deletion played tumoritoxic and tumoristatic
roles by halting the proliferation of tumor cells and enhancing their apoptosis,
suppressing angiogenesis, and inducing an anti-tumor immune response.
Nonetheless, the deletion of CXCR2 also increased the induction of fibrosis and
increased metastasis (Purohit 2015).

Taken together, we believe that CXCR2

signaling in the CAFs inhibits the myofibroblast phenotype and induces a
phenotype with a secretory function. In the present study, we demonstrate that
CXCR2 signaling interaction in CAFs causes them to assume a phenotype that is
characterized with lower expression of αSMA and ECM proteins, and higher
expression of pro-tumorigenic secreted factors including immunosuppressive
cytokines and tumor-supporting chemokines. We demonstrate that this phenotype
is mediated through activating NF-κB transcription factor activity.
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RESULTS
Kras-dependent paracrine inter-talk between CAFs and PDAC cells
In the beginning, we sought to find out if there is a paracrine inter-talk
between tumor cells and CAFs. We utilized unidirectional coculture techniques for
this purpose. The proliferation of PDAC cells was measured following treatment
with conditioned media collected from the CAFs ImPSC (murine) or 10-32 PC Puro
(human). Relative to the treatment with serum-free media, ImPSC promoted the
growth of tumor cells with activated oncogenic Kras (KC) while inhibiting cells with
wildtype Kras (Panc02) (Figure 4.1A). Similarly, the conditioned media of human
CAFs cell line 10-32 PC Puro enhanced the growth of CD18/HPAF-Scr that
possesses oncogenic Kras and has a control vector while inhibited the growth of
BxPC3 cells (with wildtype Kras) as well as CD18/HPAF-Kras kd (with oncogenic
Kras knockdown) (Figure 4.1B).

Next, we decided to investigate if the Kras-

dependent differential response present also in CAFs treated with PDAC cells
conditioned media. Conditioned media of PDAC cells carrying oncogenic Kras
mutation (KC) inhibited the growth of ImPSC cells contrary to wildtype cells
(Panc02) that enhanced CAFs growth (Figure 4.1C); and similarly, BxPC3 cells
and CD18/HPAF-Kras kd cells conditioned media promoted the growth of 10-32
PC Puro CAFs, when the CD18/HPAF-Scr has inhibited their growth (Figure
4.1D).
To confirm this observation, we utilized immortalized human pancreatic
duct-derived cell lines that express exogenous Kras(G12D) (HPNE-Kras) or normally
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express wildtype Kras (HPNE). The conditioned media of 10-32 PC Puro cells
enhanced the growth of HPNE-Kras; whereas, HPNE-Kras conditioned media
inhibited the growth of 10-32 PC Puro cells while HPNE conditioned media
promoted it (Figure 4.2). Together, the observations we described here indicate
the presence of Kras-dependent response orchestrated through paracrine factors
secreted by tumor cells and stromal cells, which could be involved in tumor
progression.
PDAC cells paracrine factors promote phenotype alterations in CAFs
When activated, fibrotic cells assume the myofibroblast phenotype that
exhibits increased ECM synthesis and is characterized by the expression of αSMA
as a marker. In cancer, myofibroblast was used synonymously to CAFs for many
years (Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015).
We decided next to investigate if the PDAC cells-derived paracrine factors have
any effect on the expression of myofibroblasts markers. ImPSC cells were treated
with conditioned media of KC cells that carry oncogenic Kras mutation, then the
expression of αSMA, Collagen I, and Collagen IV was examined. KC conditioned
media downregulated the mRNA expression of αSMA (Acta2) and the ECM
proteins Collagen I (Col1A1) and Collagen IV (Col4A1) (Figure 4.3A). Protein
levels of αSMA determined by immunofluorescence and western blot showed that
conditioned media of KC cells had decreased the expression of αSMA in ImPSC
(Figure 4.3B). We gather from this that oncogenic Kras promotes the secretion of
paracrine factors that can alter CAFs away from their typical myofibroblast
phenotype.
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PDAC cells paracrine factors induce secretion of pro-tumor cytokines and
chemokines in CAFs
Ohlund et al. described the presence of a CAFs phenotype with a higher
secretory function and a lower fibrotic function that arises through paracrine
signaling (Ohlund, Handly-Santana et al. 2017). To determine if the Kras promoted
CAFs phenotype alterations, we assessed the expression of multiple cytokines and
chemokines. We analyzed the mRNA levels of multiple cytokines and chemokines
in ImPSC cells treated with conditioned media of KC cells in comparison to serumfree media control. The analysis of mRNA levels indicated several changes in the
expression of multiple cytokines (Figure 4.4A). Notably, IL6 expression was
downregulated contrary to expectations (Figure 4.4B). Nonetheless, the most
significant changes observed as upregulation of cytokines that are considered protumorigenic by promoting immunosuppressive conditions in cancer (Matsuo,
Takeyama et al. 2012, Suzuki, Leland et al. 2015) including IL4, IL10, and IL13
(Figure 4.4C). Additionally, CXCR2 chemokines are known to play an adverse role
in PDAC mainly by promoting tumorigenesis, immunosuppression and
angiogenesis (Strieter, Burdick et al. 2006, Highfill, Cui et al. 2014, Purohit, Varney
et al. 2016). Analysis of CXCR2 chemokines revealed enhanced mRNA
expression of CXCL2 and CXCL7 in response to the KC conditioned media
treatment (Figure 4.5A-B). Analysis of the levels of chemokines in the supernatant
of ImPSC cells showed that CAFs express baseline high levels of CXCL1 and
CXCL5, moderate levels of CXCL2 and lower levels of CXCL7. Treating CAFs with
conditioned media of KC cells did not increase CXCL1 or CXCL5 but slightly
increased CXCL2 and significantly increased CXCL7 (Figure 4.5C). Taken
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together, we demonstrate that the activation of oncogenic Kras in PDAC promotes
the secretion of paracrine factors that contribute to modulating CAFs by altering
them into a phenotype with more secretory function and lower fibrogenic features.
CXCR2 signaling in CAFs promotes the secretory phenotype in CAFs
The paracrine factors CXCL1-3 and CXCL5-8 signal through CXCR2
chemokine receptor (Bizzarri, Beccari et al. 2006, Strieter, Burdick et al. 2006).
Our group has previously demonstrated the presence of a link between the
activation of oncogenic Kras and the upregulation of CXCR2 axis in PDAC
(Purohit, Varney et al. 2016). The stromal ablation of CXCR2 increased the fibrotic
reaction in the syngeneic KC mouse model of PDAC suggesting a role of CXCR2
signaling in regulating the fibrotic component in PDAC (Purohit 2015). Thus, we
decided to investigate if CXCR2 signaling is involved in the CAFs phenotype
alterations. First, we confirmed that our CAF cell lines express CXCR2 using
immunofluorescence (Figure 4.6A); then we used ELISA to measure CXCR2
ligands concentrations in the conditioned media of PDAC cells. KC conditioned
media expressed more CXCL1, CXCL5 and CXCL7 than Panc02 (Figure 4.6B),
and CD18/HPAF-Scr produced more CXCL8 than both BxPC3 (Figure 4.6C). We
treated ImPSC cells with conditioned media of KC cells in the presence or absence
of CXCR2 pharmacological inhibitors. Blocking CXCR2 reduced the inhibitory
effect of KC conditioned media and increased the growth stimulatory effect of
Panc02 (Figure 4.7A).

Recombinant CXCL1 exhibited a dose-dependent

inhibition in the growth of ImPSC cells similar to growth inhibition induced by
treating 10-32 PC Puro cells with a recombinant CXCL8 that was reduced with
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CXCR2 inhibitor (Figure 4.7B). Lastly, ImPSC cells treated with recombinant
CXCL1 downregulated Acta2 (SMA) and Col1A1 (Collagen I) and upregulated IL4,
IL13 (Figure 4.7C) and CXCL7 (Figure 4.7D). Hereby, we provided evidence that
signaling through CXCR2 is involved in altering CAFs towards the secretory
phenotype.
CXCR2 signaling in CAFs activates NF-κB
NF-κB is a transcription factor that has strong ties to both inflammation and
cancer (DiDonato, Mercurio et al. 2012). Furthermore, oncogenic Kras and CXCR2
have been reported to contribute to tumor progression through NF-κB (Richmond
2002, Ling, Kang et al. 2012, Walana, Wang et al. 2018). Lastly, a new report
described that NF-κB activation gives rise to a secretory subset of CAFs in breast
and lung cancers that express GPR77 and CD10, which could be new markers for
the secretory CAFs (Su, Chen et al. 2018). So, to investigate the involvement of
the CXCR2 signaling in CAFs in NF-κB activation and CD10 expression. ImPSC
cells treated with KC conditioned media and 10-32 PC Puro cells treated with
CXCL8 showed increase NF-κB nuclear translocation, an indication of increased
NF-κB activity. Blocking CXCR2 was able to reduce this NF-κB activity (Figure
4.8A). CD10 expression in ImPSC cells was not changed in response to KC
conditioned media; whereas, 10-32 PC puro cells had low expression of CD10 that
was slightly increased after CXCL8 treatment (Figure 4.8B). Collectively, we
demonstrate that CXCR2 signaling in CAFs of PDAC causes activation of NF-κB
that causes CAFs to assume a secretory phenotype.
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DISCUSSION
PDAC, one of the most malignant tumors, is characterized by both tumorsupporting inflammation and abundant desmoplastic reaction (Chu, Kimmelman et
al. 2007, Kleeff, Beckhove et al. 2007, Grivennikov, Greten et al. 2010, Baumgart,
Chen et al. 2014, Hamada, Masamune et al. 2014). Oncogenic Kras that occur
early during PDAC progression is associated with inflammatory signals such as
CXCR2 (Baumgart, Chen et al. 2014, Purohit, Varney et al. 2016). CXCR2
signaling in many cancer, including PDAC, has been proven adverse by
contributing

to

tumor

growth,

immunosuppression,

angiogenesis

and

chemotherapy resistance (Waugh and Wilson 2008, Matsuo, Raimondo et al.
2009, Singh, Varney et al. 2009, Highfill, Cui et al. 2014, Chan, Hsu et al. 2016,
Purohit, Varney et al. 2016, Kumar, Donthireddy et al. 2017, Su, Chen et al. 2018).
CAFs are the major contributors to desmoplasia in many cancers including PDAC
(Apte, Wilson et al. 2013, Gore and Korc 2014, Moir, Mann et al. 2015, McCarthy,
El-Ashry et al. 2018). Desmoplasia adds to tumorigenicity by supporting therapy
hindrance and resistance, and metastasis (Olive, Jacobetz et al. 2009, Pandol,
Edderkaoui et al. 2009, Bynigeri, Jakkampudi et al. 2017). CAFs for long have
been regarded as myofibroblasts characterized by expression of αSMA and ECM
proteins (Apte, Wilson et al. 2013, Moir, Mann et al. 2015). Although CAFs have
been known to secrete several paracrine factors, including CXCR2 ligands
(Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Chan, Hsu et al. 2016), it is
only recently that this secretory function gained enough attention. Recent reports
described distinct CAFs subsets with a specialized secretory function (Ohlund,
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Handly-Santana et al. 2017, Su, Chen et al. 2018). Several studies suggested the
presence of a relationship between CXCR2 signaling and stromal activity (Ijichi,
Chytil et al. 2011, Steele, Karim et al. 2016). Our group has demonstrated that
stromal ablation of CXCR2 enhances fibrosis (Purohit 2015). The secretory CAFs
phenotype was described to develop when there is no adjacency to the tumor cells
(Ohlund, Handly-Santana et al. 2017), which suggests the involvement of farreaching paracrine molecules such as CXCR2 ligands. The purpose of the present
study was to determine the role of oncogenic Kras-CXCR2 axis in CAFs activity
and function in PDAC.
Our data indicate a growth stimulatory effect of CAFs-derived paracrine
factor on PDAC cells with oncogenic Kras but not PDAC cells with wildtype Kras.
On the other hand, PDAC cells-derived paracrine factors stimulated CAFs growth
when the cells had wildtype Kras and inhibited CAFs growth when the cells had
oncogenic Kras mutation. This Kras-dependent response was shown to extend
beyond tumor cells proliferation to alter the expression of myofibroblast CAFsassociated proteins, including αSMA and ECM synthesis and to upregulates protumor cytokines and chemokines. By investigating the putative mechanisms by
which these CAFs phenotype alterations occurred, we determined that CXCR2
signaling in CAFs is involved. Blocking CXCR2 ameliorated the inhibitory effect of
the oncogenic Kras tumor cells paracrine factors and further enhanced the
stimulatory effect of wildtype cells. Furthermore, recombinant CXCR2 ligands
treatment altered the expressions profile in CAFs to reduce myofibroblasts
markers and to upregulate pro-tumor paracrine factors. Lastly, we determined that
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the CXCR2-induced secretory function in CAFs is mediated through NF-κB
activation. We also confirmed that the secretory phenotype express CD10, a
marker that has been recently linked to secretory CAFs in breast and lung cancers
(Su, Chen et al. 2018).
It is known that CAFs population is heterogeneous by cell origins (Öhlund,
Elyada et al. 2014); however, functional heterogeneity is rather a recent concept.
Myofibroblast is the typical CAFs phenotype; but, there is more attention now to
subsets of CAFs with a specialized secretory function (Ohlund, Handly-Santana et
al. 2017, Su, Chen et al. 2018). Albeit, the notion of secretory roles of CAFs is not
new. It is known that CAFs express many receptors and secrete many paracrine
factors; however, this was mainly attributed to CAFs versatility rather than
specialized functional subsets (Omary, Lugea et al. 2007, Apte, Wilson et al. 2013,
Moir, Mann et al. 2015). Looking into literature, we can find some reports that have
described what it seems to be an abundant secretory function in CAFs.
Chemotherapy treatment of CAFs of breast cancer and PDAC induced
senescence and activated inflammatory transcription factors including NF-κB and
STAT1, which resulted in upregulation of CXCR2 ligands that induced
chemotherapy resistance by promoting cancer stemness (Chan, Hsu et al. 2016).
Senescent CAFs have been reported to assume secretory functions. For example,
senescent CAFs were reported to produce inflammatory mediators such as CXCL8
and IL-6, which contributed to tumor growth, tumor cells migration, and epithelial
differentiation alteration (Parrinello 2005, Lawrenson, Grun et al. 2010, Wang,
Notta et al. 2017). Both oncogenic Kras and CXCR2 have links to senescence,
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which is mediated through activation of inflammatory transcription factors such as
NF-κB (Acosta, O'Loghlen et al. 2008, Acosta, O'Loghlen et al. 2008, Vizioli,
Santos et al. 2014, Lesina, Wormann et al. 2016).
Markers such αSMA, FAP, and PDGFR have been utilized to identify CAFs
(Omary, Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015).
Nonetheless, targeting CAFs using αSMA depletion rendered an adverse outcome
by accelerating tumor progression as a result of enhanced therapy resistance and
immunosuppression (Özdemir, Pentcheva-Hoang et al. 2014, Rhim, Oberstein et
al. 2014). Based on our current knowledge, we believe that the adverse outcome
was a consequence of increasing the abundance of the secretory CAFs. Taken
together, it is clear that the markers that have been heavily utilized are likely not
uniformly expressed on CAFs but it is not clear if this because of CAFs origin or
functional heterogeneity. We are warranted to dive into the CAFs biology and attain
better markers that allow targeting CAFs safely. There is not much we know about
putative markers for the secretory CAFs. In PDAC, the secretory CAFs were
described to express FAP and to have a low expression of αSMA (Ohlund, HandlySantana et al. 2017). The secretory CAFs described in breast, and lung cancer
had a similar expression of αSMA, FAP, and PDGFR to the other CAFs; however,
they were identified using other surface markers such as GPR77 and CD10 (Su,
Chen et al. 2018). CD10, a small metalloprotease, is known as a prognostic marker
in hematological malignancies (Maguer-Satta, Besancon et al. 2011). In solid
tumors, CD10 is considered a prognostic marker in certain tumors including
melanoma, breast, and lung cancers (Shipp, Tarr et al. 1991, Carrel, Zografos et
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al. 1993, Chu and Arber 2000, Iwaya, Ogawa et al. 2002). Stromal cells that
express CD10 have been identified in several cancers including colorectal cancer,
breast cancer, gastric cancer, and PDAC (Iwaya, Ogawa et al. 2002, Ogawa,
Iwaya et al. 2002, Huang 2005, Ikenaga, Ohuchida et al. 2010). In PDAC, CD10+
CAFs promoted tumor cells growth and was associated with reduced survival and
nodal metastasis (Ikenaga, Ohuchida et al. 2010). It is not clear; however, if all the
CD10+ CAFs carry out a secretory function or if all the secretory CAFs express
CD10.
In conclusion, we report in this study that the sustained CXCR2 signaling in
CAFs of PDAC promotes activation of NF-kB and produces a secretory phenotype
characterized by the production of pro-tumor paracrine mediator, low fibrogenic
potentials, and expression of CD10. These findings add to our current knowledge
about CAFs heterogeneity. Further studies are needed to fully characterize CAFs
and determine if the abundance of specific subsets of CAFs is associated with
certain cancer outcomes.
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Figure 4.1: Kras status of PDAC cells determines the growth response in
tumor cells and CAFs
(A) The proliferation of murine PDAC cell lines (KC and Panc02) treated with
conditioned media of the CAFs cell line (ImPSC) relative to serum-free media
treatment. (B) The proliferation of human PDAC cell lines treated with conditioned
media of the CAFs cell line (10-32 PC Puro) relative to serum-free media
treatment. (C) The proliferation of ImPSC cells treated with conditioned media of
PDAC cell lines relative to serum-free media treatment. (D) The proliferation of the
human CAFs cell line (10-32 PC Puro) treated with conditioned media of PDAC
cell lines relative to serum-free media treatment. Data are presented as mean ±
SEM. Statistical analysis was performed using Student's t-test or two-way ANOVA
when appropriate. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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Figure 4.2: Kras-dependent differential proliferation response
(A) The proliferation of immortalized human pancreatic ductal cell lines treated with
conditioned media of the CAFs cell line (10-32 PC Puro) relative to serum-free
media treatment. (B) The proliferation of the human CAFs cell line (10-32 PC Puro)
treated with conditioned media of pancreatic ductal cell lines relative to serum-free
media treatment. Data are presented as mean ± SEM. Statistical analysis was
performed using Student's t-test. *p ≤ 0.05, **p ≤ 0.01.
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Figure 4.3: Paracrine factors of PDAC cells downregulates myofibroblasts
markers
(A) Expression, determined by qPCR, of Acta2 (αSMA), Col1A1 (Collagen I) and
Col4A1 (Collagen IV) in ImPSC cells treated with KC conditioned media relative to
serum-free media treatment. (B) Representative microscopic image of αSMA
expression, determined by IF, in ImPSC cells treated with KC conditioned media
or serum-free media. Data are presented as mean ± SEM. Statistical analysis was
performed using Student's t-test. *p ≤ 0.05, **p ≤ 0.01. Scale bar = 50µm.
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Figure 4.4: PDAC cells-derived factors promote the secretion of
immunosuppressive cytokines from CAFs
(A) Expression, determined by qPCR, of selected cytokines in ImPSC cells treated
with KC conditioned media relative to serum-free media treatment. (B) Expression,
determined by qPCR, of IL6 in ImPSC cells treated with KC conditioned media
relative to serum-free media treatment. (C) Expression, determined by qPCR, of
IL4, IL10, and IL13 in ImPSC cells treated with KC conditioned media relative to
serum-free media treatment. Data are presented as mean ± SEM. Statistical
analysis was performed using Student's t-test. *p ≤ 0.05, **p ≤ 0.01.
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Figure 4.5: PDAC paracrine factors enhances production of CXCR2 ligands
(A) Expression, determined by qPCR, of CXCL1, CXCL2, and CXCL5 in ImPSC
cells treated with KC conditioned media relative to serum-free media treatment.
(B) Expression of CXCL7, determined by qPCR, and concentration of CXCL7,
determined by ELISA in ImPSC cells treated with KC conditioned media compared
to serum-free media treatment. (C) The concentration of CXCL1, CXCL2, CXCL5,
and CXCL7, as determined by ELISA, in the supernatant of ImPSC cells treated
with KC conditioned media or serum-free media for 24, 48, or 72h. Data are
presented as mean ± SEM. Statistical analysis was performed using Student's ttest or two-way ANOVA when appropriate. *p ≤ 0.05, **p ≤ 0.01.
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Figure 4.6: Higher expression of CXCR2 ligands in PDAC cells with
oncogenic Kras
(A) Representative microscopic image of CXCR2 expression, determined by IF, in
ImPSC and 10-32 PC Puro CAFs. (B) The concentration of CXCL1, CXCL2,
CXCL5, and CXCL7, as determined by ELISA, in the conditioned media of KC and
Panc02 cells. (C) The concentration of CXCL8, as determined by ELISA, in the
conditioned media of CD18/HPAF scr and BxPC3 cells. Data are presented as
mean ± SEM. Statistical analysis was performed using Student's t-test. *p ≤ 0.05,
**p ≤ 0.01. Scale bar = 50µm.
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Figure 4.7: CXCR2 signaling in CAFs induces a secretory phenotype
(A) The proliferation of ImPSC cells treated with conditioned media of PDAC cell
lines ± CXCR2 inhibitors relative to serum-free media treatment. (B) The
proliferation of the ImPSC cells treated with increasing concentrations of
recombinant CXCL1 and the proliferation of 10-32 PC Puro cells treated with
recombinant CXCL8 ± CXCR2 inhibitors relative to serum-free media treatment.
Data are presented as mean ± SEM. (C) Expression, determined by qPCR, of
Acta2, Col1A1, IL4 and IL13 in ImPSC cells treated with recombinant CXCL1
relative to serum-free media treatment. (D) Expression of CXCL7, determined by
qPCR, and concentration of CXCL7, determined by ELISA in ImPSC cells treated
with recombinant CXCL1 compared to serum-free media treatment. Statistical
analysis was performed using Student's t-test or two-way ANOVA when
appropriate. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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Figure 4.8: CXCR2 signaling induces secretory CAFs via activating NF-kB
(A) Representative immunofluorescence image of p50 in 10-32 PC Puro cells
treated with recombinant CXCL8 or serum-free media. (B) Representative
immunofluorescence image of CD10 in ImPSC cells treated with KC conditioned
media or serum-free media. Scale bar = 50µm.
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ABSTRACT
PDAC is a very ferocious and challenging malignancy with a characteristic of
predominant desmoplasia. CAFs, ECM deposition, and infiltrating immune and
endothelial cells make up the complex tumor microenvironment of PDAC. CAFs
are known for their role in ECM deposition and remodeling, which creates firm
tumors that hinders chemotherapy and modulates metastasis. Recently, a
specialized subset of CAFs was described to have an association with amplifying
inflammation. We aimed to investigate if the abundance of a certain subset of
CAFs is associated with certain cancer outcome. To examine this, we utilized
syngeneic mouse models of PDAC. Our results demonstrate that oncogenic Kras
associated with the abundance of the secretory CAFs and immune infiltration;
whereas, myofibroblasts were associated with increased fibrosis. Inhibition of
CXCR2 was beneficial in tumors abundant in myofibroblast CAFs. Together, we
demonstrate the functional heterogeneity of CAFs in PDAC and that CAFs
orientation impacts the tumor outcome.
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INTRODUCTION
PDAC is one of the most virulent solid tumors in human due to its frequent
spread, late diagnosis, and therapy resistance (Siegel, Miller et al. 2018).
Accumulation of genetic mutations, including early events such as oncogenic Kras
activation and late events including the inactivation of tumor suppressors such as
p53 and Smad4, contribute to tumor initiation and progression (Hansel, Kern et al.
2003, Hruban and Fukushima 2007, Hruban, Maitra et al. 2007, Hruban and Adsay
2009). Nonetheless, more tumor progression cues also produced as a result of
cross-talk between tumor cells and other host cells in the tumor microenvironment
that include CAFs, immune cells and endothelial cells (Chu, Kimmelman et al.
2007, Kleeff, Beckhove et al. 2007). CAFs population consists of fibrotic cells of
different origins including PSCs, tissue-resident fibroblasts, bone marrow-derived
mesenchymal cells, and fibrocytes (Öhlund, Elyada et al. 2014). As CAFs, these
cells contribute to tumor progression and spread by modulating ECM synthesis
and remodeling as well as the secretion of several paracrine factors (Omary,
Lugea et al. 2007, Apte, Wilson et al. 2013, Moir, Mann et al. 2015). Recently,
more attention has been directed towards CAFs functional heterogeneity.
Myofibroblast CAFs are the typical phenotype that is known to produce ECM
molecules contributing to tumor stiffness, hypoxia and impairing chemotherapy
delivery (Olive, Jacobetz et al. 2009, Apte, Wilson et al. 2013, Moir, Mann et al.
2015). The recently reported secretory CAF phenotype is characterized by a low
expression of αSMA and increased secretion of inflammatory and pro-tumor
mediators (Ohlund, Handly-Santana et al. 2017, Su, Chen et al. 2018). The CAFs
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secreted factors enhance tumor growth, immunosuppression, and chemotherapy
resistance by the induction of stemness (Chan, Hsu et al. 2016, Su, Chen et al.
2018).
In the previous chapter, we described how oncogenic Kras and CXCR2
signaling contribute to the secretory CAFs orientation. In this section, we aimed to
assess the impact of PDAC mutations and CXCR2 inhibition on CAFs orientation
and the overall tumor outcome. To achieve this, we utilized syngeneic PDAC
mouse models orthotopically transplanted with KC cells (oncogenic Kras) (Purohit
2015) or Panc02 (contains a single nucleotide polymorphism in Kras gene from
TAT to TAC at codon 32 and Smad4 inactivation mutation) (Wang, Zhang et al.
2012). To assess the effect of CXCR2 inhibition, the syngeneic models were
performed in mice with Cxcr2-/- or CXCR2-wildtype genotypes.

131

RESULTS
Genetic mutations in PDAC determine CAFs orientation and abundance
We have determined thus far that oncogenic Kras upregulates CXCR2 axis,
which in turn controls CAFs orientation and activity. To investigate if the PDAC
mutations can exhibit differential CAFs distribution and abundance in-vivo, we
utilized syngeneic mouse models transplanted with KC cells that carry oncogenic
Kras (Torres, Rachagani et al. 2013) or Panc02 that carry wildtype Kras (Wang,
Zhang et al. 2012). Histological assessment of KC tumor exhibited welldifferentiated tumors with abundant duct formation, low to moderate infiltration of
CAFs, and a high inflammatory infiltration, in particular, polymorph nuclear cells
that are likely neutrophils or MDSCs (Figure 5.1A). Panc02 tumors were
undifferentiated with no to little duct formation, and a high infiltration of CAFs
(Figure 5.1B). To assess CAFs orientation, we used immunohistochemistry
technique to stain for αSMA and CD10. In KC tumor, few αSMA+ cells were found
often between ducts and at the tumor margins; interestingly, CD10 staining was
localized to the αSMA areas but also stained much more area where αSMA was
negative (Figure 5.1C). This indicates that αSMA+ CAFs are also likely CD10+,
which may represent the myofibroblast population; whereas, CD10+ CAFs that are
negative for αSMA staining represent secretory CAFs. Lastly, CAFs distribution in
Panc02 tumors indicated that both αSMA and CD10 staining were localized to the
same areas suggesting that CAFs in Panc02 tumors are likely assumed the
myofibroblast phenotype (Figure 5.1D). Together, we show that Kras status of
PDAC can affect CAFs phenotypes orientation and abundance.
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CXCR2 inhibition renders different impact based on PDAC mutations
Our interest in investigating CAFs of PDAC was as a result to the
observation that inhibiting CXCR2 in the syngeneic KC mouse model rendered
increased fibrosis revealing a potential role of CXCR2 in regulating CAFs (Purohit
2015). In this section, we aimed to investigate the effect of the stromal CXCR2
deletion in the context of PDAC mutations. We utilized the syngeneic PDAC model
of KC and Panc02 that were implanted in Cxcr2-/- or wildtype. From our previous
study (Purohit 2015), we concluded that CXCR2 deletion caused tumoristatic and
tumoritoxic effects by halting proliferation and increasing apoptosis of tumor cells,
lowering MDSCs infiltration, and decreasing angiogenesis. Our focus here was to
assess the impact of CXCR2 deletion on CAFs and if it is linked to other changes
in the context of oncogenic Kras. In KC tumors, deletion of CXCR2 did not exhibit
alteration to the differentiation stage of the tumor cells; however, the major
observation was the increase of fibrotic reaction (Figure 5.2A). The increased
fibrotic reaction in the KC model was associated with increased αSMA+ cells that
were also localized to the same area as CD10+ CAFs suggesting a diminished
secretory CAFs repertoire (Figure 5.2B). CXCR2 knockout in Panc02 implanted
mice seemed to have a more prominent anti-tumor effect. In addition to increasing
the tumor cells apoptosis, the decreased vascularization was more noticeable in
these tumors. Moreover, CXCR2 stromal deletion appears to ameliorate the
aggressiveness of the tumor cells in Panc02 tumors, which was presented as
increased ducts formation indicating a transformation from undifferentiated to
poorly-differentiated tumor (Figure 5.2C). Finally, similar to CXCR2-wildtype
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tumors, both αSMA and CD10 staining localized to the same areas of the sections,
and there was no noticeable change to fibrotic reaction or the abundance of CAFs
(Figure 5.2C). Collectively, we demonstrate a mutation-dependent histological
difference in PDAC and show that CXCR2 plays a role in both tumors and stromal
compartments.
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DISCUSSION
Both the tumor-supporting inflammation and the dense desmoplasia are
typical characteristics of PDAC (Chu, Kimmelman et al. 2007, Kleeff, Beckhove et
al. 2007, Grivennikov, Greten et al. 2010, Baumgart, Chen et al. 2014, Hamada,
Masamune et al. 2014). CAFs are now considered a player in both hallmarks by
assuming distinct functional phenotypes. Myofibroblasts produce ECM causing
tumor stiffness and hypoxia; thus, promoting therapy hindrance and contributing
to metastasis (Olive, Jacobetz et al. 2009, Pandol, Edderkaoui et al. 2009,
Bynigeri, Jakkampudi et al. 2017). Secretory CAFs secrete paracrine mediators
and modulate inflammation, immunosuppression, and chemotherapy resistance
(Waugh and Wilson 2008, Matsuo, Raimondo et al. 2009, Singh, Varney et al.
2009, Highfill, Cui et al. 2014, Chan, Hsu et al. 2016, Purohit, Varney et al. 2016,
Kumar, Donthireddy et al. 2017, Su, Chen et al. 2018). In this section, we used
syngeneic mouse models to assess the involvement of PDAC mutations and the
involvement of CXCR2 in tumors’ histological features. PDAC tumors with only
oncogenic Kras mutation presented well-differentiated histological features, with
increased polymorph nuclear cells infiltration and abundance of secretory CAFs.
Disrupting stromal CXCR2 signaling, caused an abundance of myofibroblast
CAFs, which was associated with the increased fibrotic reaction. On the other
hand, the tumors with wildtype Kras and Smad4 inactivating mutation presented
undifferentiated tumors with an abundance of CAFs that were mostly
myofibroblasts. CXCR2 deletion in these tumors produced a more pronounced
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anti-tumor effect by forming poorly-differentiated tumors with decreased
angiogenesis.
Targeting CAFs as well as targeting CXCR2 has been attempted before,
which exhibited beneficial outcomes in some cases and adverse outcomes in
others cases. Targeting CAFs or desmoplasia improved chemotherapy delivery in
some instances and accelerated tumor progression in other cases (Olive, Jacobetz
et al. 2009, Özdemir, Pentcheva-Hoang et al. 2014, Rhim, Oberstein et al. 2014).
Inhibiting CXCR2 in the context of Kras mutation alone, increased the fibrosis and
metastasis (Purohit 2015); whereas, CXCR2 inhibition in the context of other
mutations, such as p53 or Tgfbr2, rendered beneficial outcomes (Ijichi, Chytil et al.
2011, Steele, Karim et al. 2016). Our data demonstrated that the pronounced antitumor effects of CXCR2 deletion were observed in tumors generated using Panc02
cells that carry a wildtype Kras and a Smad4 mutation (Wang, Zhang et al. 2012).
Oncogenic Kras mutation occurs early during PDAC pathogenesis; whereas,
mutations of the tumor suppressors are often late events (Hruban and Fukushima
2007). This observation could suggest a temporal context for the beneficial or
adverse outcomes of CXCR2 inhibition, in which inhibiting CXCR2 in early PDAC
could render accelerated disease and inhibiting CXCR2 in late stages could tame
the disease.
In conclusion, we report in this study that CXCR2 signaling plays a role in
regulating the CAFs of PDAC; thus, affecting the tumor outcome. Further studies
are required to characterize CAFs subsets and identify better markers than
currently available. Furthermore, there is a need for better understating for the
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temporal and mutation context of CXCR2 roles in PDAC. We have witnessed that
both targeting CAFs and targeting CXCR2 could have context-dependent
outcomes. Both could still be good potential targets for treating PDAC, pending
better understanding.
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Figure 5.1: Kras-dependent CAFs distribution in-vivo
(A) Representative image with H&E staining of tumors derived from KC implanted
syngeneic mouse models showing the well-differentiated histology (left) and the
abundant polymorph nuclear cells infiltration (right). (B) Representative image with
H&E staining of tumors derived from Panc02 implanted syngeneic mouse models
showing the undifferentiated histology (left) and the abundant CAFs infiltration
(right). (C) Representative immunohistochemistry images of tumors derived from
KC implanted syngeneic mouse models showing αSMA staining (left) and CD10
staining (right). (D) Representative immunohistochemistry images of tumors
derived from Panc02 implanted syngeneic mouse models showing αSMA staining
(left) and CD10 staining (right). Scale bar = 100µm.
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Figure 5.2: CXCR2 inhibition affects stromal activity in-vivo
(A) Representative immunohistochemistry images with H&E or Masson’s
trichrome staining of tumors derived from KC implanted syngeneic mouse models.
(B) Representative immunohistochemistry images of tumors derived from KC
implanted syngeneic mouse models showing αSMA or CD10 staining. (C)
Representative immunohistochemistry images with H&E or Masson’s trichrome
staining of tumors derived from Panc02 implanted syngeneic mouse models. (D)
Representative immunohistochemistry images of tumors derived from KC
implanted syngeneic mouse models showing αSMA or CD10 staining. Scale bar =
100µm.

141

CHAPTER VI: MAJOR CONCLUSIONS AND FUTURE DIRECTIONS

142

INTRODUCTION
Pancreatic cancers, in general, rank the fourth in leading causes of cancer
deaths in the United States (Siegel, Miller et al. 2018). PDAC is the most common
subtype of pancreatic cancers, and one of the most virulent human cancers. The
lack of early screening tools and the asymptomatic nature of the disease cause
the late detection that is often at the metastatic stage. A small proportion of PDAC
patients are diagnosed with a localized tumor. At such stage, surgical resection
may provide a cure for the disease. Patient diagnosed with advanced stages miss
the chance for effective therapeutic options. The virulence of PDAC comes from
its frequent dissemination, resistance to conventional therapy, and the high
recurrence rates even for those patients who underwent surgical resection
(Hidalgo 2010). There is an urgent need to develop screening and early detection
options as well as to develop effective therapies for advanced PDAC.
Understanding the complex tumor-stromal and stromal-stromal interactions,
underlined with understanding the driving genetic alterations can aid in the quest
for developing both detection tool and therapeutic potentials. Our effort in this study
aimed to investigate the relationship between oncogenic Kras mutation, CXCR2
signaling, and CAFs. We also sought to examine the role of CAFs in PDAC in light
of CXCR2 signaling CAFs heterogeneity.
The adverse role of CAFs in PDAC as enablers of therapy resistance and
metastasis is established (Olive, Jacobetz et al. 2009, Xing, Saidou et al. 2010,
Apte, Wilson et al. 2013, Moir, Mann et al. 2015, Su, Chen et al. 2018). CAFs
functional heterogeneity has gained momentum recently. Myofibroblast CAFs, the
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typical phenotype, develop in response to factors including TGF-β, PDGF and
SHH, and contribute to desmoplasia by promoting ECM deposition (Shek, Fmj et
al. 2002, Omary, Lugea et al. 2007, Bailey, Swanson et al. 2008). The recently
described secretory CAFs are thought to develop in the context of inflammation
through paracrine stimulation (Ohlund, Handly-Santana et al. 2017, Su, Chen et
al. 2018). CAFs-secreted paracrine factors promote tumor virulence (Polnaszek,
Kwabi-Addo et al. 2003, Chan, Hsu et al. 2016). This dissertation summarizes the
putative role of oncogenic Kras-driven inflammation, in particular, CXCR2
signaling, in CAFs orientation and function, and explains how CXCR2 ligands and
other paracrine factors such as FGF-2 shape up the tumor cells behavior and
affects the overall tumor outcome. The first section of this chapter is a summary of
the major findings and conclusions of this dissertation. The next section presents
the future directions for this project by discussing the uninvestigated questions and
suggestions of experiments to answer them.
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MAJOR CONCLUSIONS
The role of FGF-2 and CXCL8 in tumor-CAFs interaction
I.

Both CAFs and PDAC cells express FGF-2 and CXCL8.

II.

Direct co-culture showed that CAFs increased the growth of the
aggressive PDAC cells but inhibited the non-aggressive cells.

III.

FGF-2 secreted by CAFs induced the growth stimulatory effect and the
secretion of CXCL8 in the aggressive PDAC cells.

IV.

CXCL8 produced by PDAC cells modulated CAFs growth and induced
secretion of FGF-2 to create a feedforward loop.

V.

Gene expression of PDAC-CAFs co-culture indicated that CAFs produce
the bulk of the pro-tumor cytokines and chemokines.

VI.

The co-culture of CAFs with PDAC cells increased the expression of
FGF-2 and CXCL8.

VII.

In addition to the pro-tumor cytokines and chemokines, CAFs co-culture
with the aggressive PDAC cells indicated that CAFs promote tumor
progression by upregulating genes such as ELMO1 that promotes tumor
cells motility and invasion.

The role of oncogenic Kras in regulating CAFs
I.

CAFs paracrine factors promote the growth of PDAC cells with oncogenic
Kras.

II.

Paracrine factors secreted from PDAC cells with oncogenic Kras inhibits
the growth of CAFs.
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III.

Oncogenic Kras-driven PDAC secreted factors alter myofibroblast
markers.

IV.

PDAC factors, in the context of oncogenic Kras, promote secretory
function in CAFs portrayed as the secretion of CXCR2 ligands and protumor cytokines.

The role of CXCR2 signaling in regulating CAFs function
I.

PDAC cells with oncogenic Kras produce more CXCR2 ligands.

II.

CXCR2 signaling induces an inhibitory effect on CAFs proliferation.

III.

CXCR2 signaling in CAFs promotes phenotypic changes to CAFs by
downregulating myofibroblast markers.

IV.

In response to CXCR2 signaling, CAFs assume a secretory function by
secreting CXCR2 ligands and pro-tumor immunosuppressive cytokines.

V.

The CXCR2-induced secretory CAF phenotype is mediated through NFκB activation.

VI.

The secretory CAFs express CD10.

CAFs phenotypes distribution in PDAC
I.

CD10 is expressed on myofibroblast in addition to αSMA; whereas;
secretory CAFs only express CD10.

II.

PDAC tissues displayed expression of both myofibroblasts and
secretory CAFs.

III.

Wildtype Kras tumors mostly presented myofibroblast phenotype (CD10
and αSMA present at the same location most of the time).
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IV.

In oncogenic Kras tumors, there is more secretory CAFs (more CD10
staining than αSMA staining).

V.

CXCR2 inhibition in oncogenic Kras produced phenotype change to
mostly myofibroblast and increased fibrosis.

VI.

CXCR2 inhibition in wildtype Kras PDAC mouse models yielded less
aggressive tumors.

The big picture
Based on our observations as well as findings from the literature, we compiled the
following conclusions:
I.

CAFs are recruited from different origins and express different markers.

II.

CAFs display functional heterogeneity as myofibroblast or secretory
phenotypes.

III.

Myofibroblasts develop in response to fibrogenic factors such as TGFβ, PDGF and SHH.

IV.

Myofibroblast CAFs produced ECM and promote tumor stiffness,
hypoxia, chemotherapy hindrance and EMT, factors that enable
invasion.

V.

Secretory CAFs develop in the context of inflammation, in response to
mediators such as CXCR2 ligands and DAMPs.

VI.

Producing pro-tumor mediators such as CXCR2 ligands and IL-6,
secretory CAFs enable tumor growth, immunosuppression, vascularity,
and stemness-induced therapy resistance (Figure 6.1).
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VII.

Oncogenic Kras that occur early in PDAC development is highly linked
to inflammation; thus, expected to display an abundance of secretory
CAFs in early stages.

VIII.

Mutations in tumor suppressors such as p53 and Smad4 are often late
events and are linked to the increased desmoplastic reaction.

IX.

The increased desmoplasia and the inactivation of the tumor
suppressors could be the tipping point for invasive PDAC.
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FUTURE DIRECTIONS
With what we currently know, based both on the current study and the
literature, about the CXCR2-dependent role of CAFs in PDAC, there still many
unanswered questions. In this section, we will discuss the major unanswered
question and their potential future direction.
CAFs origin and CAFs functional role
CAFs compartment develops from fibrotic cells of different origins, including
PSCs, tissue-resident fibroblasts, bone marrow-derived mesenchymal stem cells
and fibrocytes (Öhlund, Elyada et al. 2014). Multiple markers, including αSMA,
FAP, and PDGFR, have been heavily utilized to distinguish CAFs from other cells;
however, these markers are not uniformly expressed on CAFs (Öhlund, Elyada et
al. 2014). It is not clear if the lack of uniform expression is due to origin disparities,
functional heterogeneity, differentiation stage, or a combination of multiple factors.
We know that secretory CAFs in PDAC have low expression of αSMA (Ohlund,
Handly-Santana et al. 2017); however, that is not the case in other cancer. The
αSMA expression in the secretory CAFs of breast and lung cancers was not
different; whereas, markers such as CD10 and GPR77 were used (Su, Chen et al.
2018). We showed that secretory CAFs express CD10, but so are myofibroblasts.
CAFs compartment in PDAC is maybe different in term of the origins of cells
compared to other cancer types. Stellate cells were reported in multiple organs,
but, are mostly described in the context of the liver and the pancreas (Omary,
Lugea et al. 2007, Apte, Wilson et al. 2013, Öhlund, Elyada et al. 2014, Moir, Mann
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et al. 2015). Recently, a subset of CAFs in breast cancer was described as bone
marrow-derived mesenchymal cells reported to have low expression of PDGFR
and to be functionally important for tumor growth and angiogenesis (Raz, Cohen
et al. 2018). This suggests that CAFs origin may be involved in functional
heterogeneity. In addition to the involvement of CAFs origin or lack thereof, it is
not clear if the distinct functional subsets of CAFs are the yield of disparities in
differentiation stage, or it is just a dynamic process in response to milieu changes,
and whether they are able to switch into one another remains unknown. It is not
clear also if other functional subsets present. There is a need for a better
characterization of CAFs marker based on their origin and differentiation stages
and cross-referenced to their functional roles. Single-cell RNA-seq and other gene
expression and the functional assays can be utilized to achieve this goal.
Temporal context of CAFs functional heterogeneity
There is a great similarity between cancer and wound healing process.
Cancers are often referred to as “wounds that do not heal” (Dvorak 1986). As
discussed before, wound healing occur as a coordinated process of inflammatory
response followed by tissue repair and remodeling. Fibrogenic activity in the
wound healing process is a late event that happens after the secession of the
inflammatory response (Dvorak 1986, Midwood, Williams et al. 2004). Similarly,
PDAC is associated with early pro-tumor inflammation that often happen in the
context of oncogenic Kras and a late pronounced desmoplasia prior to the
emergence of invasive PDAC that occur after inactivation of tumor suppressors
including p53 and Smad4 (Hruban, Offerhaus et al. 1998, Hruban, Wilentz et al.
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2000, Purohit, Varney et al. 2016). This temporal context of genetic alterations
alongside the transformation from inflammation to desmoplasia suggests a timely
CAFs phenotype conversion. We know that targeting CAFs have been attempted
before with opposing outcomes (Olive, Jacobetz et al. 2009, Özdemir, PentchevaHoang et al. 2014). It is possible that targeting the right subset of CAFs in the right
time could yield a beneficial result. Materials required to achieve this purpose
include PDAC progression models with inducible mutations.
CXCR2 in the context of PDAC mutations and progression
Similar to targeting desmoplasia, inhibiting CXCR2 produced opposing
outcomes (Ijichi, Chytil et al. 2011, Purohit 2015, Steele, Karim et al. 2016), which
may involve mutation and/or progression context. With only oncogenic Kras
mutation, CXCR2 deletion was adverse; whereas, the beneficial outcome was
observed when CXCR2 was inhibited in the context of tumor suppressors’
mutations (Ijichi, Chytil et al. 2011, Purohit 2015, Steele, Karim et al. 2016). Thus,
CXCR2 could have opposing roles and targeting CXCR2 in the right context can
produce advantageous effects. We can utilize PDAC progression models.
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Figure 6.1: CAFs distribution affects the tumor outcome
Tumors abundant in myofibroblasts are characterized by increased ECM
deposition that contributes to hypoxia and tumor stiffness, increased EMT, and a
tendency for metastasis. The abundance of secretory CAFs contributes to tumor
growth as a result of vascularization and proliferation cues, promotes
immunosuppression by recruiting MDSCs, and enhances chemotherapy
resistance by increasing stemness.
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